Eurasian,MISC
J,O
Med,O
2020,DATE
;,O
52,NUMBER
(,O
2,NUMBER
),O
:,O
191,NUMBER
‐,O
6,NUMBER
Aycan,O
Yuksel1,O
.,O
Dilek,PERSON
Karado,PERSON
‐,O
gan2,O
.,O
Canan,PERSON
Gunduz,PERSON
Gurkan3,PERSON
.,O
Fatma,PERSON
Tokgoz,PERSON
Akyil4,PERSON
.,O
Zehra,PERSON
Nur,PERSON
Toreyin5,O
.,O
Feride,O
Marim6,O
.,O
Huseyin,PERSON
Arikan7,PERSON
.,O
Tugba,PERSON
Sismanlar,PERSON
Eyuboglu8,O
.,O
Nagehan,PERSON
Emiralioglu9,PERSON
.,O
Irem,O
Serifoglu10,O
.,O
Elif,PERSON
De,PERSON
‐,PERSON
veli11,O
.,O
Selman,PERSON
Celik12,O
.,O
Umran,PERSON
Ozden,PERSON
Sertcelik13,O
.,O
Tugba,PERSON
Ramasli,PERSON
Gursoy8,O
.,O
Mehmet,PERSON
Fatih,PERSON
Elversli14,PERSON
.,O
Asli,O
Oncel13,O
.,O
Berrin,PERSON
Er15,O
.,O
Ali,PERSON
Firincioglulari16,PERSON
.,O
Fatma,PERSON
Esra,PERSON
Gunaydin17,PERSON
.,O
Hilal,PERSON
Ozakinci18,PERSON
.,O
Neslihan,PERSON
Ozcelik2,PERSON
.,O
Dorina,PERSON
Esendagli19,PERSON
.,O
Asena,O
Aydin20,O
.,O
Nesli,O
‐,O
han,O
Kose21,O
.,O
Merve,PERSON
Ercelik22,PERSON
.,O
Pinar,PERSON
Yildiz,PERSON
Gulhan22,O
.,O
Ethem,PERSON
Yildiz23,O
.,O
Ilim,O
Irmak13,O
.,O
Bilge,PERSON
Yilmaz,PERSON
Kara2,O
.,O
Selcuk,PERSON
Gurz24,PERSON
.,O
Fatma,PERSON
Gulsum,PERSON
Karakas25,PERSON
.,O
Metin,PERSON
Akgun26,O
To,O
know,O
what,O
you,O
know,O
and,O
what,O
you,O
do,O
not,O
know,O
.,O
that,O
is,O
true,O
knowledge,O
Eurasian,MISC
J,O
Med,O
2020,DATE
;,O
52,NUMBER
(,O
2,NUMBER
),O
:,O
191,NUMBER
‐,O
6,NUMBER
.,O
Department,O
of,O
Chest,O
Diseases,CAUSE_OF_DEATH
.,O
Recep,PERSON
Tayyip,PERSON
Depart,PERSON
‐,PERSON
ment,O
of,O
Chest,O
Diseases,CAUSE_OF_DEATH
.,O
Sureyyapasa,ORGANIZATION
Chest,ORGANIZATION
Diseases,ORGANIZATION
and,O
Thoracic,O
Surgery,ORGANIZATION
Training,ORGANIZATION
and,ORGANIZATION
Research,ORGANIZATION
Hospital,ORGANIZATION
.,O
Istanbul,CITY
.,O
Turkey,COUNTRY
Depart,O
‐,O
ment,O
of,O
Chest,O
Diseases,CAUSE_OF_DEATH
.,O
Yedikule,ORGANIZATION
Chest,ORGANIZATION
Diseases,ORGANIZATION
and,O
Thoracic,O
Surgery,ORGANIZATION
Training,ORGANIZATION
and,ORGANIZATION
Research,ORGANIZATION
Hospital,ORGANIZATION
.,O
Istanbul,CITY
.,O
Turkey,COUNTRY
Depart,O
‐,O
ment,O
of,O
Occupational,ORGANIZATION
Health,ORGANIZATION
and,O
Diseases,CAUSE_OF_DEATH
.,O
Adana,ORGANIZATION
City,ORGANIZATION
Research,ORGANIZATION
and,O
Training,ORGANIZATION
Hospital,ORGANIZATION
.,O
Adana,CITY
.,O
Turkey,COUNTRY
Department,O
of,O
Chest,O
Diseases,CAUSE_OF_DEATH
.,O
Kutahya,CITY
Kutahya,CITY
.,O
Turkey,COUNTRY
Center,LOCATION
.,O
Internal,ORGANIZATION
Medicine,ORGANIZATION
Intensive,ORGANIZATION
Care,ORGANIZATION
Unit,O
.,O
Van,PERSON
.,O
Turkey,ORGANIZATION
Department,ORGANIZATION
of,ORGANIZATION
Pediatric,ORGANIZATION
Pulmonology,ORGANIZATION
.,O
Gazi,PERSON
De,PERSON
‐,PERSON
partment,O
of,O
Pediatric,ORGANIZATION
Pulmonology,ORGANIZATION
.,O
Hacettepe,ORGANIZATION
Department,ORGANIZATION
of,ORGANIZATION
Chest,ORGANIZATION
Diseases,CAUSE_OF_DEATH
Kirikhan,LOCATION
State,LOCATION
Hospital,LOCATION
.,O
Hatay,LOCATION
.,O
Turkey,COUNTRY
Department,O
of,O
Physiotherapy,O
and,O
Rehabilitation,O
.,O
Istanbul,CITY
.,O
Turkey,COUNTRY
Department,O
of,O
Nursing,O
and,O
Health,ORGANIZATION
Services,ORGANIZATION
.,O
Istanbul,CITY
.,O
Turkey,COUNTRY
Department,LOCATION
of,LOCATION
Chest,LOCATION
Diseases,CAUSE_OF_DEATH
.,O
Hacettepe,ORGANIZATION
Department,ORGANIZATION
of,ORGANIZATION
Chest,ORGANIZATION
Diseases,ORGANIZATION
.,O
Unye,O
State,O
Hos,O
‐,O
pital,O
.,O
Ordu,ORGANIZATION
.,O
Turkey,COUNTRY
Scientists,O
from,O
all,O
over,O
the,O
world,O
have,O
been,O
intensively,O
working,O
to,O
discover,O
different,O
aspects,O
of,O
Coronavirus,O
disease,CAUSE_OF_DEATH
2019,DATE
(,O
COVID,O
‐,O
19,NUMBER
),O
since,O
the,O
first,ORDINAL
cluster,O
of,O
cases,O
was,O
re,O
‐,O
ported,O
in,O
China,COUNTRY
.,O
Herein,O
.,O
we,O
aimed,O
to,O
investigate,O
unclear,O
issues,O
related,O
to,O
transmission,O
and,O
pathogenesis,O
of,O
disease,CAUSE_OF_DEATH
as,O
well,O
as,O
accuracy,O
of,O
diagnostic,O
the,O
asymptomatic,O
phase,O
of,O
infection,CAUSE_OF_DEATH
.,O
and,O
viral,O
load,O
was,O
suggested,O
to,O
be,O
a,O
useful,O
marker,TITLE
to,O
assess,O
disease,CAUSE_OF_DEATH
severity,O
.,O
In,O
contrast,O
to,O
immune,O
response,O
against,O
viral,O
infec,O
‐,O
tions,O
.,O
cytotoxic,O
T,O
lymphocytes,O
decline,O
in,O
SARSCoV,O
‐,O
2,NUMBER
infection,CAUSE_OF_DEATH
.,O
which,O
can,O
be,O
partially,O
explained,O
by,O
direct,O
invasion,O
of,O
T,O
lympho,O
‐,O
cytes,O
or,O
apoptosis,O
activated,O
by,O
SARS,O
‐,O
CoV,O
‐,O
2,NUMBER
.,O
Dysregulation,O
of,O
the,O
urokinase,O
pathway,O
.,O
cleavage,O
of,O
the,O
SARS,O
‐,O
CoV,O
‐,O
2,NUMBER
Spike,O
protein,O
by,O
FXa,O
and,O
FIIa,O
.,O
and,O
consumption,O
coagulopathy,O
were,O
the,O
proposed,O
mechanisms,O
of,O
the,O
coagulation,O
dysfunction,O
in,O
COVID,O
‐,O
19,NUMBER
.,O
False,O
‐,O
neg,O
‐,O
ative,O
rates,O
of,O
reverse,O
transcriptase,O
polymerase,O
chain,O
reaction,O
varied,O
between,O
3,PERCENT
%,PERCENT
and,O
41,PERCENT
%,PERCENT
across,O
studies,O
.,O
The,O
probability,O
of,O
the,O
positive,O
test,O
was,O
proposed,O
to,O
decrease,O
with,O
the,O
number,O
of,O
days,DURATION
past,DATE
from,O
symptom,O
onset,O
.,O
Safety,O
issues,O
related,O
to,O
infection,CAUSE_OF_DEATH
spread,O
limit,O
the,O
use,O
of,O
high,O
flow,O
nasal,O
oxygen,O
(,O
HFNO,O
),O
and,O
contin,O
‐,O
uous,O
positive,O
airway,O
pressure,O
(,O
CPAP,O
),O
in,O
hypoxic,O
patients,O
.,O
Further,O
studies,O
are,O
required,O
to,O
elucidate,O
the,O
challenging,O
issues,O
.,O
thus,O
enhancing,O
the,O
management,O
of,O
COVID,O
‐,O
19,NUMBER
patients,O
.,O
Keywords,O
:,O
Coron,PERSON
‐,O
avirus,O
.,O
pathogenesis,O
.,O
transmission,O
.,O
venous,O
thromboembolism,O
Coron,O
‐,O
avirus,O
disease,CAUSE_OF_DEATH
2019,DATE
(,O
COVID,O
‐,O
19,NUMBER
),O
is,O
an,O
infectious,CAUSE_OF_DEATH
disease,CAUSE_OF_DEATH
mostly,O
effects,O
the,O
lungs,O
caused,O
by,O
a,O
novel,O
betacoronavirus,O
.,O
SARS,O
‐,O
CoV,O
‐,O
2,NUMBER
.,O
which,O
was,O
first,ORDINAL
described,O
in,O
December,DATE
2019,DATE
.,O
in,O
China,COUNTRY
.,O
and,O
was,O
later,O
declared,O
as,O
the,O
cause,O
of,O
a,O
pandemic,O
.,O
Despite,O
the,O
similarity,O
of,O
the,O
genetic,O
sequencing,O
of,O
the,O
novel,O
coronavirus,O
with,O
the,O
SARS,O
virus,O
.,O
the,O
management,O
of,O
this,O
unknown,O
disease,CAUSE_OF_DEATH
with,O
non,O
‐,O
specific,O
manifestations,O
is,O
still,O
very,O
challenging,O
for,O
the,O
physicians,MISC
[,O
1,NUMBER
],O
.,O
Patients,O
with,O
COVID,O
‐,O
19,NUMBER
present,DATE
with,O
a,O
variety,O
of,O
incubation,O
peri,O
‐,O
od,O
as,O
well,O
as,O
clinical,O
course,O
of,O
the,O
disease,CAUSE_OF_DEATH
.,O
COVID19,O
pneumonia,CAUSE_OF_DEATH
may,O
lead,O
to,O
shock,O
and,O
multiple,O
organ,O
failure,O
.,O
In,O
most,O
cases,O
.,O
res,O
‐,O
piratory,O
failure,O
accounts,O
for,O
the,O
actual,O
cause,O
of,O
death,O
.,O
The,O
es,O
‐,O
timated,O
global,O
mortality,O
rate,O
is,O
approximately,O
2,PERCENT
%,PERCENT
.,O
but,O
it,O
varies,O
according,O
to,O
age,O
[,O
1,NUMBER
],O
.,O
It,O
is,O
important,O
to,O
define,O
the,O
severity,O
of,O
the,O
disease,CAUSE_OF_DEATH
since,O
severe,O
patients,O
experience,O
worse,O
outcomes,O
.,O
Al,O
‐,O
though,O
scientists,O
from,O
all,O
over,O
the,O
world,O
have,O
been,O
trying,O
to,O
un,O
‐,O
ravel,O
the,O
complexity,O
of,O
COVID,O
‐,O
19,NUMBER
.,O
yet,O
much,O
remains,O
to,O
be,O
learned,O
in,O
regards,O
to,O
pathogenesis,O
of,O
the,O
disease,CAUSE_OF_DEATH
.,O
accuracy,O
of,O
diagnostic,O
tests,O
and,O
treatment,O
modalities,O
.,O
The,O
present,DATE
of,O
Medical,O
Subject,O
Headings,O
(,O
MeSH,O
),O
search,O
terms,O
Coronavirus,O
.,O
Coronavirus,O
Infections,CAUSE_OF_DEATH
.,O
192,NUMBER
Yuksel,PERSON
et,O
al,O
.,O
The,O
Unknowns,O
of,O
COVID,O
‐,O
19,NUMBER
Eurasian,O
J,O
Med,O
2020,DATE
;,O
52,NUMBER
(,O
2,NUMBER
),O
:,O
191,NUMBER
‐,O
6,NUMBER
Novel,O
coronavirus,O
pneumonia,CAUSE_OF_DEATH
.,O
COVID,O
.,O
Acute,O
Respirato,O
‐,O
ry,O
Syndrome,O
.,O
SARS,O
‐,O
CoV,O
‐,O
2,NUMBER
.,O
Reference,O
lists,O
of,O
the,O
studies,O
were,O
al,O
‐,O
so,O
checked,O
through,O
to,O
find,O
more,O
studies,O
that,O
are,O
pertinent,O
than,O
English,NATIONALITY
were,O
excluded,O
.,O
Pathogenesis,O
of,O
COVID,O
‐,O
19,NUMBER
infection,CAUSE_OF_DEATH
re,O
‐,O
mains,O
unclear,O
.,O
a,O
variety,O
of,O
potential,O
pathogenic,O
mechanisms,O
in,O
‐,O
cluding,O
coagulopathy,O
.,O
thrombotic,O
microangiopathy,O
restricted,O
to,O
lungs,O
.,O
endothelial,O
dysfunction,O
.,O
excessive,O
release,O
of,O
pro,O
‐,O
inflam,O
‐,O
matory,O
cytokines,O
are,O
being,O
investigated,O
.,O
The,O
endothelial,O
dysfunc,O
‐,O
tion,O
caused,O
by,O
infection,CAUSE_OF_DEATH
activates,O
an,O
excessive,O
thrombin,O
genera,O
‐,O
tion,O
and,O
inhibits,O
fibrinolysis,O
.,O
which,O
indicates,O
hypercoagulabili,O
‐,O
ty,O
[,O
2,NUMBER
],O
.,O
For,O
instance,O
.,O
lung,O
dissection,O
of,O
a,O
deceased,O
patient,O
with,O
COVID,O
‐,O
19,NUMBER
pneumonia,CAUSE_OF_DEATH
showed,O
blockage,O
and,O
establishment,O
of,O
small,O
thrombosis,CAUSE_OF_DEATH
in,O
pulmonary,O
microvasculature,O
[,O
3,NUMBER
],O
.,O
Coagulopathy,O
and,O
thrombotic,O
microangiopathy,O
will,O
be,O
discussed,O
in,O
detail,O
below,O
in,O
subsection,O
of,O
Coagulation,O
dysfunction,O
and,O
venous,O
thromboembolism,O
in,O
patients,O
with,O
COVID,O
‐,O
19,NUMBER
.,O
Internal,ORGANIZATION
Medicine,ORGANIZATION
Intensive,ORGANIZATION
Care,ORGANIZATION
Unit,O
.,O
Hacettepe,ORGANIZATION
Health,ORGANIZATION
Sciences,ORGANIZATION
.,O
Ankara,CITY
Ataturk,O
Chest,O
Diseases,CAUSE_OF_DEATH
and,O
Thoracic,ORGANIZATION
Surgery,ORGANIZATION
Training,ORGANIZATION
and,ORGANIZATION
Research,ORGANIZATION
Hospital,ORGANIZATION
.,O
Ankara,CITY
.,O
Tur,O
‐,O
key,O
Department,ORGANIZATION
of,ORGANIZATION
Allergy,ORGANIZATION
and,ORGANIZATION
Immunology,ORGANIZATION
.,O
Uludag,ORGANIZATION
Department,ORGANIZATION
of,O
Chest,O
Diseases,CAUSE_OF_DEATH
.,O
Kestel,ORGANIZATION
State,ORGANIZATION
Hospital,ORGANIZATION
.,O
Bursa,CITY
.,O
Turkey,COUNTRY
Department,LOCATION
of,O
Chest,O
Diseases,CAUSE_OF_DEATH
.,O
Bilecik,ORGANIZATION
State,ORGANIZATION
Hospital,ORGANIZATION
.,O
Bilecik,PERSON
.,O
Turkey,COUNTRY
De,O
‐,O
partment,O
of,O
Chest,O
Diseases,CAUSE_OF_DEATH
.,O
Bingol,CITY
State,LOCATION
Hopital,LOCATION
.,O
Bingl,LOCATION
.,O
Turkey,COUNTRY
Department,O
of,O
Thoracic,O
Surgery,CAUSE_OF_DEATH
.,O
Ondokuz,PERSON
Mayis,PERSON
Department,PERSON
of,PERSON
Chest,PERSON
Diseases,CAUSE_OF_DEATH
.,O
Istanbul,CITY
Medicine,LOCATION
.,O
Istanbul,CITY
.,O
Turkey,COUNTRY
Correspondence,O
to,O
:,O
Dilek,PERSON
Karadogan,PERSON
SARS,O
‐,O
CoV,O
‐,O
2,NUMBER
enters,O
target,O
cells,O
with,O
the,O
spike,O
(,O
S,O
),O
protein,O
engaging,O
angiotensin,O
converting,O
enzyme,O
‐,O
2,NUMBER
(,O
ACE2,O
),O
receptor,O
[,O
4,NUMBER
],O
.,O
The,O
virus,O
will,O
proliferate,O
and,O
cause,O
destruction,O
of,O
the,O
tis,O
‐,O
sues,O
which,O
have,O
high,O
ACE2,O
expression,O
including,O
lungs,O
.,O
intestines,O
.,O
kidneys,O
when,O
protective,O
immune,O
response,O
is,O
impaired,O
.,O
The,O
major,O
‐,O
histocompatibility,O
‐,O
complex,O
antigen,O
loci,O
(,O
HLA,O
),O
seem,O
to,O
be,O
respon,O
‐,O
sible,O
for,O
predisposition,O
to,O
infections,CAUSE_OF_DEATH
.,O
For,O
instance,O
.,O
some,O
murine,O
MHC,O
class,O
II,NUMBER
haplotypes,O
are,O
related,O
to,O
predisposition,O
with,O
in,O
‐,O
fluenza,O
.,O
HLA,O
‐,O
A,O
*,O
11,NUMBER
.,O
HLA,O
‐,O
B,O
*,O
35,NUMBER
.,O
and,O
HLADRB1,O
*,O
10,NUMBER
make,O
males,O
vulnerable,O
to,O
H1N1,O
[,O
5,NUMBER
],O
.,O
During,O
the,O
incubation,O
and,O
early,O
phase,O
of,O
the,O
dis,O
‐,O
ease,O
.,O
a,O
specific,O
adaptive,O
immune,O
response,O
may,O
stop,O
SARS,O
‐,O
CoV,O
‐,O
2,NUMBER
and,O
prevent,O
worsening,O
[,O
6,NUMBER
],O
.,O
The,O
cellular,O
immunity,O
.,O
T,O
lymphocytes,O
are,O
major,O
players,O
in,O
virus,O
clearance,O
after,O
viral,O
infections,CAUSE_OF_DEATH
.,O
Lym,O
‐,O
phopenia,O
is,O
one,NUMBER
of,O
the,O
most,O
prominent,O
characteristics,O
of,O
COVID,O
‐,O
19,NUMBER
[,O
7.8.9,NUMBER
],O
.,O
and,O
might,O
be,O
explained,O
by,O
the,O
impaired,O
innate,O
and,O
adap,O
‐,O
tive,O
immune,O
responses,O
.,O
In,O
contrast,O
to,O
the,O
immune,O
response,O
against,O
viral,O
infections,CAUSE_OF_DEATH
.,O
cytotoxic,O
T,O
lymphocytes,O
decline,O
sharply,O
in,O
SARSCoV,O
‐,O
2,NUMBER
infection,CAUSE_OF_DEATH
[,O
10,NUMBER
],O
.,O
A,O
study,O
demonstrated,O
that,O
reduction,O
of,O
CD3,O
+,O
.,O
CD4,O
+,O
and,O
CD8,O
+,O
T,O
lymphocytes,O
were,O
related,O
to,O
the,O
course,O
of,O
COVID,O
‐,O
19,NUMBER
pneumonia,CAUSE_OF_DEATH
.,O
especially,O
in,O
severe,O
cases,O
[,O
11,NUMBER
],O
.,O
The,O
mecha,O
‐,O
nism,O
of,O
the,O
reduction,O
of,O
T,O
lymphocytes,O
may,O
be,O
a,O
result,O
of,O
the,O
di,O
‐,O
rect,O
assault,CRIMINAL_CHARGE
of,O
SARS,O
‐,O
COV,O
‐,O
2,NUMBER
or,O
induction,O
of,O
apoptosis,O
by,O
SARCoV,O
‐,O
2,NUMBER
like,O
MERS,O
‐,O
CoV,O
[,O
12,NUMBER
],O
.,O
In,O
addi,O
‐,O
tion,O
.,O
SARS,O
‐,O
CoV,O
‐,O
2,DATE
may,DATE
modify,O
role,O
of,O
antigen,O
presenting,O
cells,O
.,O
dendritic,O
cells,O
.,O
and,O
cytokines,O
(,O
TNF,O
‐,O
al,O
‐,O
fa,O
and,O
IL,STATE_OR_PROVINCE
‐,O
4,NUMBER
),O
which,O
regulate,O
the,O
function,O
of,O
T,O
lymphocytes,O
[,O
13.14,NUMBER
],O
.,O
The,O
immune,O
status,O
differs,O
significantly,O
between,O
severe,O
and,O
nonsevere,O
COVID,O
‐,O
19,NUMBER
patients,O
[,O
15,NUMBER
],O
.,O
The,O
reduction,O
of,O
T,O
‐,O
Cells,O
correlates,O
with,O
disease,CAUSE_OF_DEATH
severity,O
.,O
May,O
here,O
lies,O
the,O
answer,O
of,O
the,O
question,O
of,O
why,O
some,O
patients,O
experience,O
severe,O
disease,CAUSE_OF_DEATH
.,O
while,O
the,O
others,O
show,O
mild,O
symptoms,O
.,O
The,O
complement,O
system,O
is,O
a,O
crucial,O
piece,O
of,O
host,TITLE
defence,O
against,O
infections,CAUSE_OF_DEATH
.,O
has,O
potent,O
pro,O
‐,O
inflam,O
‐,O
matory,O
properties,O
and,O
can,O
aggravate,O
lung,O
injury,O
.,O
and,O
may,O
play,O
a,O
part,O
in,O
COVID,O
‐,O
19,NUMBER
pneumonia,CAUSE_OF_DEATH
.,O
Complement,O
activation,O
in,O
the,O
patho,O
‐,O
genesis,O
of,O
SARS,O
had,O
been,O
shown,O
before,O
[,O
16,NUMBER
],O
.,O
and,O
a,O
recent,O
study,O
revealed,O
that,O
complement,O
C3,O
was,O
remarkably,O
elevated,O
in,O
serious,O
cases,O
of,O
COVID,O
‐,O
19,NUMBER
pneumonia,CAUSE_OF_DEATH
than,O
that,O
in,O
non,O
‐,O
serious,O
cases,O
[,O
11,NUMBER
],O
.,O
The,O
cytokine,O
release,O
syndrome,O
(,O
CRS,O
),O
may,O
play,O
a,O
major,O
role,O
in,O
pa,O
‐,O
tients,O
with,O
severe,O
COVID,O
‐,O
19,NUMBER
as,O
in,O
ARDS,O
.,O
Pro,O
‐,O
inflammatory,O
cy,O
‐,O
tokines,O
that,O
drive,O
progression,O
of,O
the,O
disease,CAUSE_OF_DEATH
including,O
IL2,O
.,O
IL6,O
.,O
IL7,O
.,O
IL10,O
.,O
GCSF,ORGANIZATION
.,O
IP10,O
.,O
MCP1,O
.,O
MIP1,O
.,O
and,O
TNF,O
are,O
reported,O
high,O
in,O
severe,O
COVID,O
‐,O
19,NUMBER
patients,O
especially,O
requiring,O
the,O
intensive,O
care,O
unit,O
(,O
ICU,O
),O
[,O
7,NUMBER
],O
.,O
The,O
pathological,O
characteristics,O
of,O
COVID,O
‐,O
19,NUMBER
re,O
‐,O
lated,O
ARDS,O
are,O
diffuse,O
alveolar,O
damage,O
with,O
hyaline,O
membrane,O
for,O
‐,O
mation,O
with,O
fibrin,O
deposition,O
and,O
a,O
few,O
multinucleated,O
enlarged,O
cells,O
[,O
17,NUMBER
],O
.,O
A,O
robust,O
immune,O
response,O
and,O
epithelial,O
regeneration,O
is,O
essential,O
for,O
recovery,O
and,O
may,O
lead,O
aberrant,O
wound,O
healing,O
which,O
can,O
cause,O
more,O
severe,O
fibrosis,O
than,O
other,O
causes,O
of,O
ARDS,O
.,O
The,O
function,O
of,O
hyaluronic,O
acid,O
(,O
HA,O
),O
is,O
insufficient,O
in,O
patients,O
with,O
influenza,CAUSE_OF_DEATH
.,O
therefore,O
.,O
COVID,O
‐,O
19,NUMBER
related,O
ARDS,O
has,O
been,O
thought,O
to,O
be,O
associated,O
with,O
HA,O
[,O
18,NUMBER
],O
.,O
Chen,O
et,O
al.,O
[,O
19,NUMBER
],O
demonstrated,O
that,O
the,O
hemoglobin,O
decreases,O
.,O
whereas,O
serum,O
ferritin,O
.,O
erythro,O
‐,O
cyte,O
sedimentation,O
rate,O
.,O
C,O
‐,O
reactive,O
protein,O
(,O
CRP,O
),O
.,O
and,O
lactate,O
dehydrogenase,O
increase,O
significantly,O
in,O
most,O
COVID,O
‐,O
19,NUMBER
cases,O
.,O
A,O
molecular,O
study,O
reported,O
genomic,O
structures,O
of,O
the,O
virus,O
inter,O
‐,O
feres,O
with,O
the,O
heme,O
on,O
the,O
1,NUMBER
‐,O
beta,O
chain,O
of,O
hemoglobin,O
to,O
seperate,O
the,O
iron,O
as,O
a,O
result,O
forming,O
porphyrin,O
[,O
20,NUMBER
],O
.,O
This,O
inhibits,O
normal,O
metabolic,O
pathway,O
of,O
heme,O
.,O
and,O
cause,O
hemoglobin,O
carry,O
less,O
oxy,O
‐,O
gen.,TITLE
Alveolocapillary,O
units,O
have,O
become,O
inable,O
to,O
transfer,O
carbon,O
dioxide,O
and,O
oxygen,O
.,O
Coagulation,O
Dysfunction,O
and,O
Venous,O
Throm,O
‐,O
boembolism,O
in,O
Patients,O
with,O
COVID,O
‐,O
19,NUMBER
As,O
clinicians,O
we,O
have,O
to,O
identify,O
the,O
variables,O
that,O
drive,O
mortality,O
early,O
.,O
Considering,O
current,DATE
data,O
.,O
we,O
have,O
to,O
focus,O
on,O
three,NUMBER
important,O
Yuksel,PERSON
et,O
al,O
.,O
The,O
Unknowns,O
of,O
COVID,O
‐,O
19,NUMBER
Eurasian,O
J,O
Med,O
2020,DATE
;,O
52,NUMBER
(,O
2,NUMBER
),O
:,O
191,NUMBER
‐,O
6,NUMBER
points,O
:,O
older,O
age,O
.,O
increased,O
value,O
of,O
D,O
‐,O
dimer,O
(,O
>,O
1g,NUMBER
/,O
ml,O
),O
.,O
and,O
pres,O
‐,O
ence,O
of,O
co,O
‐,O
morbidities,O
[,O
21,NUMBER
],O
.,O
The,O
role,O
of,O
coagulopathy,O
in,O
COVID,O
‐,O
19,NUMBER
needs,O
to,O
be,O
clarified,O
.,O
In,O
a,O
previous,O
study,O
.,O
it,O
was,O
sug,O
‐,O
gested,O
that,O
impairment,O
of,O
the,O
urokinase,O
pathway,O
promotes,O
to,O
lung,O
involvement,O
whereas,O
plasminogen,O
activator,O
inhibitor,O
‐,O
1,NUMBER
defends,O
against,O
SARS,O
[,O
22,NUMBER
],O
.,O
Moreover,O
.,O
Beri,PERSON
et,O
al.,O
revealed,O
that,O
fibrinoly,O
‐,O
sis,O
activated,O
by,O
plasminogen,O
aggravates,O
inflammation,O
caused,O
by,O
influenza,CAUSE_OF_DEATH
[,O
23,NUMBER
],O
.,O
Abnormal,O
coagulation,O
results,O
are,O
associated,O
with,O
poor,O
prognosis,O
.,O
Disseminated,O
intravascular,O
coagulation,O
(,O
DIC,O
),O
is,O
common,O
in,O
deceased,O
COVID,O
‐,O
19,NUMBER
patients,O
.,O
In,O
a,O
study,O
.,O
D,O
‐,O
dimer,O
.,O
fib,O
‐,O
rin,O
/,O
fibrinogen,O
degradation,O
products,O
(,O
FDP,O
),O
and,O
fibrinogen,O
levels,O
were,O
higher,O
in,O
patients,O
with,O
COVID,O
‐,O
19,NUMBER
than,O
those,O
in,O
healthy,O
con,O
‐,O
trols,O
.,O
while,O
antithrombin,O
level,O
was,O
lower,O
[,O
24,NUMBER
],O
.,O
In,O
addition,O
.,O
lev,O
‐,O
els,O
of,O
D,O
‐,O
dimer,O
and,O
FDP,ORGANIZATION
in,O
cases,O
with,O
severe,O
COVID,O
‐,O
19,NUMBER
were,O
higher,O
than,O
cases,O
with,O
mild,O
disease,CAUSE_OF_DEATH
.,O
A,O
study,O
compared,O
the,O
coagulation,O
parameters,O
between,O
patients,O
with,O
severe,O
pneumonia,CAUSE_OF_DEATH
caused,O
by,O
SARS,O
‐,O
CoV2,O
and,O
nonSARS,O
‐,O
CoV2,O
.,O
and,O
also,O
evaluated,O
whether,O
cases,O
with,O
high,O
levels,O
of,O
D,O
‐,O
dimer,O
could,O
benefit,O
from,O
anticoagulants,O
[,O
25,NUMBER
],O
.,O
The,O
28,NUMBER
‐,O
day,DURATION
mortality,O
was,O
approximately,O
twice,O
fold,O
higher,O
in,O
patients,O
with,O
COVID,O
‐,O
19,NUMBER
compared,O
to,O
non,O
‐,O
COVID,O
cases,O
.,O
COVID,O
‐,O
19,NUMBER
cases,O
had,O
higher,O
platelet,O
counts,O
.,O
The,O
28,NUMBER
‐,O
day,DURATION
mortality,O
in,O
COVID,O
‐,O
19,NUMBER
pa,O
‐,O
tients,O
with,O
D,O
‐,O
dimer,O
>,O
3.0,NUMBER
g,O
/,O
mL,O
.,O
who,O
received,O
anticoagulants,O
were,O
lower,O
than,O
who,O
did,O
not,O
receive,O
and,O
cases,O
with,O
high,O
levels,O
of,O
D,O
‐,O
dimer,O
could,O
benefit,O
from,O
anticoagulants,O
.,O
A,O
study,O
from,O
China,COUNTRY
demonstrated,O
that,O
D,O
‐,O
dimer,O
and,O
FDP,O
levels,O
.,O
prothrombin,O
time,O
and,O
activated,O
partial,O
thromboplastin,O
time,O
are,O
significantly,O
higher,O
in,O
deceased,O
patients,O
with,O
COVD,O
‐,O
19,NUMBER
compared,O
to,O
survivors,O
;,O
and,O
71.4,PERCENT
%,PERCENT
of,O
non,O
‐,O
survivors,O
met,O
the,O
criteria,O
of,O
DIC,ORGANIZATION
whereas,O
only,O
0.6,PERCENT
%,PERCENT
of,O
survivors,O
did,O
[,O
25,NUMBER
],O
.,O
Development,O
of,O
consumption,O
coagulopathy,O
.,O
es,O
‐,O
pecially,O
DIC,O
.,O
may,O
worsen,O
the,O
clinical,O
course,O
in,O
patients,O
with,O
COVID,O
‐,O
19,NUMBER
.,O
DIC,ORGANIZATION
is,O
not,O
so,O
rare,O
in,O
patients,O
with,O
severe,O
SARS,O
‐,O
Cov,O
‐,O
2,NUMBER
infection,CAUSE_OF_DEATH
.,O
and,O
the,O
rate,O
of,O
DIC,ORGANIZATION
in,O
deceased,O
patients,O
was,O
reported,O
71.4,NUMBER
[,O
26,NUMBER
],O
.,O
Monitoring,O
of,O
coagulation,O
parameters,O
may,O
help,O
to,O
pre,O
‐,O
dict,O
deterioration,O
of,O
the,O
disease,CAUSE_OF_DEATH
and,O
establish,O
an,O
accurate,O
ther,O
‐,O
apeutic,O
strategy,O
.,O
Severe,O
COVID,O
‐,O
19,NUMBER
can,O
progress,O
to,O
sepsis,CAUSE_OF_DEATH
which,O
also,O
a,O
common,O
cause,O
of,O
DIC,ORGANIZATION
.,O
through,O
inflammatory,O
cytokines,O
such,O
as,O
IL,STATE_OR_PROVINCE
‐,O
6,NUMBER
.,O
IL,STATE_OR_PROVINCE
‐,O
8,NUMBER
.,O
TNF,O
‐,O
.,O
Prevalence,O
of,O
venous,O
thromboembolism,O
(,O
VTE,O
),O
in,O
patients,O
with,O
SARS,O
‐,O
CoV,O
‐,O
2,NUMBER
infection,CAUSE_OF_DEATH
remains,O
unclear,O
.,O
The,O
inci,O
‐,O
dence,O
of,O
VTE,O
in,O
patients,O
with,O
severe,O
COVID,O
‐,O
19,NUMBER
who,O
were,O
admitted,O
to,O
ICUs,O
was,O
found,O
to,O
be,O
25,PERCENT
%,PERCENT
in,O
a,O
retrospective,O
study,O
analyzing,O
ultrasound,O
of,O
lower,O
extremity,O
vein,O
[,O
27,NUMBER
],O
.,O
Antiphospholipid,O
anti,O
‐,O
bodies,O
are,O
detected,O
in,O
high,O
titers,O
in,O
antiphospholipid,O
syndrome,O
;,O
however,O
.,O
they,O
can,O
also,O
appear,O
temporarily,O
in,O
critical,O
patients,O
.,O
Zhang,PERSON
et,O
al.,O
[,O
28,NUMBER
],O
described,O
three,NUMBER
patients,O
with,O
SARS,O
‐,O
CoV,O
‐,O
2,NUMBER
infec,O
‐,O
tion,O
who,O
had,O
coagulation,O
dysregulation,O
and,O
antiphospholipid,O
anti,O
‐,O
bodies,O
.,O
including,O
anticardiolipin,O
IgA,O
.,O
anti,O
‐,O
2,NUMBER
‐,O
glycoprotein,O
I,O
IgA,O
.,O
and,O
IgG,O
antibodies,O
.,O
and,O
also,O
intracerebral,O
infarcts,O
.,O
A,O
post,O
‐,O
mortem,O
study,O
reported,O
COVID,O
‐,O
19,NUMBER
associated,O
cardiopulmonary,O
changes,O
as,O
follows,O
[,O
29,NUMBER
],O
:,O
The,O
main,O
pulmonary,O
arteries,O
were,O
free,O
of,O
thromboemboli,O
;,O
hyaline,O
membranes,O
consistent,O
with,O
diffuse,O
alveolar,O
damage,O
with,O
mild,O
‐,O
to,O
‐,O
moderate,O
lymphocytic,O
infiltrates,O
(,O
CD4,O
im,O
‐,O
munostain,O
pozitive,O
),O
;,O
fibrin,O
thrombi,O
and,O
megakaryocytes,O
in,O
capil,O
‐,O
laries,O
and,O
small,O
vessels,O
;,O
cardiomegaly,O
.,O
and,O
right,O
ventricular,O
di,O
‐,O
latation,O
.,O
There,O
are,O
nor,O
thrombus,O
in,O
coronary,O
arteries,O
neither,O
lymphocytic,O
infiltrate,O
in,O
myocard,O
suggestive,O
of,O
viral,O
myocardi,O
‐,O
tis,O
.,O
The,O
dominant,O
processes,O
seem,O
to,O
be,O
diffuse,O
alveolar,O
damage,O
.,O
CD4,O
+,O
mononuclear,O
cell,O
infiltration,O
around,O
occluded,O
small,O
vessels,O
by,O
microthrombi,O
.,O
and,O
pulmonary,O
hemorrhage,CAUSE_OF_DEATH
.,O
Thrombotic,O
microan,O
‐,O
giopathy,O
is,O
considered,O
restricted,O
to,O
the,O
lungs,O
.,O
Coagulopathy,O
be,O
‐,O
comes,O
more,O
prominent,O
on,O
the,DATE
seventh,DATE
day,DATE
of,O
viremia,O
.,O
One,NUMBER
theory,O
suggests,O
that,O
anticoagulants,O
could,O
block,O
SARS,O
‐,O
CoV,O
‐,O
2,NUMBER
replication,O
through,O
inhibiting,O
cleavage,O
of,O
the,O
S,O
protein,O
by,O
FXa,O
and,O
FIIa,O
.,O
Low,O
molecular,O
weight,O
heparins,O
(,O
LMWHs,O
),O
are,O
suggested,O
in,O
treatment,O
of,O
hospitalized,O
adult,O
patients,O
with,O
COVID,O
‐,O
19,NUMBER
.,O
The,O
International,O
So,O
‐,O
ciety,O
on,O
Thrombosis,CAUSE_OF_DEATH
and,O
Haemostasis,O
(,O
ISTH,O
),O
recently,DATE
recommended,O
that,O
all,O
hospitalized,O
COVID,O
‐,O
19,NUMBER
patients,O
.,O
even,O
those,O
not,O
in,O
the,O
ICU,O
.,O
should,O
receive,O
standard,O
prophylactic,O
anticoagulation,O
with,O
LMWH,ORGANIZATION
in,O
the,O
absence,O
of,O
any,O
contraindications,O
.,O
Early,O
application,O
of,O
anticoagulants,O
is,O
being,O
advocated,O
for,O
better,O
disease,CAUSE_OF_DEATH
course,O
in,O
severe,O
COVID,O
‐,O
19,NUMBER
.,O
however,O
.,O
it,O
remains,O
unclear,O
whether,O
we,O
should,O
use,O
specific,O
inclusion,O
or,O
exclusion,O
criteria,O
.,O
ISTH,ORGANIZATION
has,O
defined,O
a,O
new,O
and,O
earlier,O
phase,O
of,O
sepsis,CAUSE_OF_DEATH
‐,O
associated,O
DIC,ORGANIZATION
.,O
called,O
sepsis,CAUSE_OF_DEATH
‐,O
in,O
‐,O
duced,O
coagulopathy,O
(,O
SIC,O
),O
[,O
30,NUMBER
],O
.,O
Preliminary,O
data,O
from,O
Wuhan,CITY
sug,O
‐,O
gest,O
that,O
anticoagulation,O
may,O
be,O
beneficial,O
in,O
severe,O
COVID,O
‐,O
19,NUMBER
cases,O
with,O
D,O
‐,O
dimer,O
levels,O
>,O
6,NUMBER
times,O
the,O
upper,O
limit,O
of,O
normal,O
[,O
31,NUMBER
],O
.,O
On,O
contrary,O
.,O
Harvard,ORGANIZATION
Brigham,ORGANIZATION
and,O
Womens,ORGANIZATION
Hospital,ORGANIZATION
guidance,O
suggests,O
initiating,O
prophylactic,O
anticoagulation,O
therapy,O
for,O
all,O
patients,O
with,O
COVID19,O
in,O
absence,O
of,O
any,O
contraindications,O
.,O
Oral,O
anticoagulants,O
should,O
be,O
switched,O
to,O
LMWH,O
or,O
unfractionated,O
hep,O
‐,O
arin,O
.,O
However,O
.,O
whether,O
anticoagulants,O
are,O
only,O
useful,O
in,O
patients,O
meeting,O
SIC,O
criteria,O
or,O
with,O
markedly,O
elevated,O
D,O
‐,O
dimer,O
but,O
not,O
in,O
unselected,O
patients,O
remains,O
to,O
be,O
unclear,O
.,O
A,O
small,O
case,O
series,O
suggested,O
that,O
dipyridamole,O
could,O
be,O
used,O
.,O
although,O
anticoagulant,O
and,O
antiplatelet,O
agents,O
need,O
further,O
investigation,O
for,O
their,O
therapeutic,O
activities,O
[,O
32,NUMBER
],O
.,O
Viral,O
Transmission,O
SARS,O
‐,O
CoV,O
‐,O
2,NUMBER
cause,O
rapid,O
spread,O
[,O
33,NUMBER
.,O
34,NUMBER
],O
.,O
even,O
among,O
asymptomatic,O
or,O
minimally,O
symp,O
‐,O
tomatic,O
carriers,O
[,O
35,NUMBER
.,O
36,NUMBER
],O
.,O
A,O
study,O
reported,O
that,O
mean,O
nasopharyn,O
‐,O
geal,O
swab,O
viral,O
load,O
of,O
severe,O
cases,O
was,O
60,NUMBER
‐,O
fold,O
higher,O
than,O
that,O
of,O
mild,O
cases,O
.,O
which,O
suggests,O
that,O
the,O
higher,O
the,O
viral,O
load,O
the,O
more,O
severe,O
the,O
disease,CAUSE_OF_DEATH
[,O
37,NUMBER
],O
.,O
Viral,O
negative,O
conversion,O
seems,O
to,O
occur,O
early,O
in,O
mild,O
cases,O
.,O
a,O
study,O
revealed,O
that,O
90,PERCENT
%,PERCENT
of,O
mild,O
group,O
have,O
negative,O
RT,O
‐,O
PCR,O
results,O
after,O
10,DURATION
days,DURATION
whereas,O
all,O
se,O
‐,O
vere,O
cases,O
yet,O
tested,O
positive,O
over,O
day,DURATION
10,NUMBER
[,O
37,NUMBER
],O
.,O
Asymptomatic,O
transmission,O
of,O
SARS,O
‐,O
CoV,O
‐,O
2,DATE
may,DATE
cause,O
challenges,O
for,O
disease,CAUSE_OF_DEATH
con,O
‐,O
trol,O
.,O
Presymptomatic,O
transmission,O
can,O
happen,O
through,O
formation,O
of,O
respiratory,O
droplets,O
or,O
indirect,O
transmission,O
.,O
Vocal,O
activi,O
‐,O
ties,O
including,O
speech,O
.,O
laughing,O
.,O
singing,O
have,O
been,O
showed,O
Envi,O
‐,O
ronmental,O
contamination,O
with,O
SARS,O
‐,O
CoV,O
‐,O
2,NUMBER
can,O
occur,O
via,O
droplet,O
dispersion,O
or,O
touching,O
with,O
an,O
infected,O
persons,O
contaminated,O
hands,O
[,O
39,NUMBER
],O
.,O
Duration,O
of,O
contagiuous,O
phase,O
while,O
a,O
patient,O
is,O
presymptomatic,O
is,O
still,O
unknown,O
.,O
A,O
study,O
demonstrated,O
that,O
1,NUMBER
‐,O
3,NUMBER
days,DURATION
prior,O
to,O
initiation,O
of,O
symptoms,O
.,O
presymptomatic,O
spread,O
expo,O
‐,O
sure,O
occurred,O
[,O
40,NUMBER
],O
.,O
Tranmission,O
and,O
viability,O
of,O
SARS,O
and,O
in,O
‐,O
fluenza,O
on,O
surfaces,O
were,O
shown,O
to,O
decrease,O
at,O
higher,O
tempera,O
‐,O
tures,O
.,O
Regard,O
to,O
this,O
.,O
higher,O
temperatures,O
were,O
proposed,O
to,O
may,O
have,O
a,O
protecting,O
impact,O
towards,O
SARS,O
‐,O
CoV,O
‐,O
2,NUMBER
infection,CAUSE_OF_DEATH
.,O
In,O
a,O
study,O
.,O
it,O
was,O
found,O
that,O
an,O
increase,O
in,O
temperature,O
from,O
1C,O
to,O
9C,O
.,O
and,O
from,O
10C,O
to,O
19C,O
was,O
associated,O
with,O
a,O
decrease,O
in,O
case,O
numbers,O
from,O
24,NUMBER
to,NUMBER
19,NUMBER
.,O
and,O
from,O
18,NUMBER
to,NUMBER
7,NUMBER
.,O
respectively,O
[,O
41,NUMBER
],O
.,O
Con,O
‐,O
trarily,O
.,O
results,O
of,O
another,O
report,O
did,O
not,O
favour,O
the,O
postulation,O
that,O
elevated,O
temperature,O
and,O
UV,O
radiation,O
can,O
decrease,O
the,O
spread,O
of,O
COVID,O
‐,O
19,NUMBER
[,O
42,NUMBER
],O
.,O
It,O
was,O
proposed,O
that,O
difference,O
in,O
mor,O
‐,O
tality,O
of,O
SARS,O
‐,O
CoV,O
‐,O
2,NUMBER
infection,CAUSE_OF_DEATH
among,O
countries,O
could,O
be,O
elucidat,O
‐,O
ed,O
by,O
Bacillus,O
Calmette,O
‐,O
Gurin,PERSON
(,O
BCG,O
),O
vaccination,O
status,O
.,O
55,NUMBER
high,O
income,O
countries,O
with,O
current,DATE
BCG,ORGANIZATION
policy,O
had,O
0.780.40,NUMBER
deaths,O
per,O
million,NUMBER
people,O
;,O
contrarily,O
.,O
countries,O
that,O
never,O
had,O
a,O
BCG,O
policy,O
including,O
Italy,COUNTRY
.,O
Netherlands,COUNTRY
.,O
Belgium,COUNTRY
.,O
USA,COUNTRY
.,O
Lebanon,COUNTRY
had,O
a,O
higher,O
mortality,O
rate,O
.,O
with,O
16.397.33,NUMBER
deaths,O
per,O
million,NUMBER
people,O
[,O
43,NUMBER
],O
.,O
Besides,O
.,O
it,O
is,O
unknown,O
whether,O
BCG,ORGANIZATION
vaccination,O
at,O
old,O
age,O
would,O
boost,O
defenses,O
in,O
elderly,O
.,O
194,NUMBER
Yuksel,PERSON
et,O
al,O
.,O
The,O
Unknowns,O
of,O
COVID,O
‐,O
19,NUMBER
Accuracy,O
of,O
Diagnostic,O
Tests,O
Test,O
designs,O
vary,O
whether,O
the,O
test,O
detects,O
infection,CAUSE_OF_DEATH
directly,O
(,O
such,O
as,O
the,O
virus,O
itself,O
),O
or,O
indirectly,O
(,O
such,O
as,O
host,TITLE
antibodies,O
),O
.,O
Countries,O
have,O
used,O
differ,O
‐,O
ent,O
testing,O
approaches,O
depending,O
on,O
their,O
testing,O
capacities,O
.,O
Current,DATE
casefatality,O
rate,O
ranges,O
from,O
0.6,PERCENT
%,PERCENT
to,O
7.2,PERCENT
%,PERCENT
by,O
region,O
[,O
44,NUMBER
‐,O
46,NUMBER
],O
.,O
In,O
a,O
couple,O
countries,O
.,O
nation,O
‐,O
wide,O
utilization,O
of,O
diag,O
‐,O
nostic,O
testing,O
became,O
a,O
mainstay,O
of,O
effective,O
confinement,O
ap,O
‐,O
proaches,O
.,O
For,O
example,O
.,O
in,O
Germany,COUNTRY
and,O
South,COUNTRY
Korea,COUNTRY
.,O
the,O
case,O
‐,O
fa,O
‐,O
tality,O
rates,O
are,O
less,O
than,O
0.5,PERCENT
%,PERCENT
.,O
probably,O
because,O
extensive,O
test,O
‐,O
ing,O
revealed,O
a,O
large,O
group,O
of,O
mild,O
cases,O
[,O
47,NUMBER
],O
.,O
Nucleic,O
acid,O
am,O
‐,O
plification,O
time,O
of,O
symptom,O
onset,O
when,O
viral,O
shedding,O
and,O
trans,O
‐,O
mission,O
risk,O
is,O
highest,O
[,O
48,NUMBER
],O
.,O
Real,O
‐,O
time,O
reverse,O
transcriptase,O
polymerase,O
chain,O
reaction,O
(,O
RT,O
‐,O
PCR,O
),O
based,O
assay,O
on,O
respiratory,O
specimens,O
performed,O
in,O
laboratory,O
is,O
the,O
reference,O
standard,O
test,O
for,O
COVID,O
‐,O
19,NUMBER
diagnosis,O
.,O
Detection,O
of,O
host,TITLE
‐,O
derived,O
antibodies,O
di,O
‐,O
rected,O
against,O
SARSCoV,O
‐,O
2,NUMBER
are,O
crucial,O
for,O
surveillance,O
.,O
determina,O
‐,O
tion,O
of,O
SARS,O
‐,O
CoV,O
‐,O
2,NUMBER
immunity,O
.,O
and,O
potentially,O
for,O
risk,O
assessment,O
of,O
health,O
care,O
workers,O
.,O
The,O
utility,O
of,O
antibody,O
detection,O
assays,O
for,O
diagnosing,O
acute,O
infections,CAUSE_OF_DEATH
is,O
probably,O
limited,O
around,O
the,O
time,O
of,O
symptom,O
onset,O
[,O
48,NUMBER
],O
.,O
Serologic,MISC
assays,O
might,O
be,O
useful,O
in,O
scenarios,O
in,O
which,O
patients,O
present,DATE
with,O
late,O
complications,CAUSE_OF_DEATH
of,O
disease,CAUSE_OF_DEATH
.,O
and,O
RT,O
‐,O
PCR,O
is,O
false,O
negative,O
due,O
to,O
reduction,O
in,O
viral,O
shedding,O
over,O
time,O
.,O
The,O
Center,ORGANIZATION
for,ORGANIZATION
Disease,ORGANIZATION
Control,ORGANIZATION
(,O
CDC,ORGANIZATION
),O
current,DATE
‐,O
ly,O
recommends,O
priority,O
for,O
testing,O
three,NUMBER
groups,O
:,O
hospitalized,O
pa,O
‐,O
tients,O
with,O
presentations,O
compatible,O
with,O
COVID,O
‐,O
19,NUMBER
.,O
other,O
sympto,O
‐,O
matic,O
persons,O
at,O
risk,O
for,O
poor,O
outcomes,O
.,O
and,O
persons,O
who,O
had,O
close,O
contact,O
with,O
someone,O
with,O
suspected,O
or,O
confirmed,O
COVID,O
‐,O
19,NUMBER
within,O
14,DURATION
days,DURATION
of,O
illness,CAUSE_OF_DEATH
onset,O
[,O
49,NUMBER
],O
.,O
The,O
CDC,ORGANIZATION
does,O
not,O
recommend,O
testing,O
asymptomatic,O
persons,O
.,O
A,O
nasopharyngeal,O
specimen,O
is,O
the,O
preferred,O
choice,O
for,O
swab,O
‐,O
based,O
testing,O
.,O
but,O
samples,O
taken,O
from,O
sputum,O
.,O
endotracheal,O
aspirates,O
.,O
and,O
bronchoalveolar,O
lavage,O
have,O
greater,O
sensitivity,O
than,O
upper,O
respiratory,O
tract,O
specimens,O
[,O
50,NUMBER
],O
.,O
Inadequate,O
sample,O
collection,O
may,O
result,O
false,O
negative,O
.,O
A,O
study,O
identified,O
that,O
the,O
likelihood,O
of,O
a,O
positive,O
RT,O
‐,O
PCR,O
test,O
reduces,O
with,O
time,O
following,O
initiation,O
of,O
symptoms,O
.,O
and,O
nasal,O
swabs,O
are,O
better,O
at,O
diagnostic,O
yield,O
than,O
throat,O
swabs,O
[,O
51,NUMBER
],O
.,O
Previous,O
stud,O
‐,O
ies,O
have,O
reported,O
rates,O
of,O
false,O
‐,O
negative,O
RT,O
‐,O
PCR,O
results,O
at,O
symp,O
‐,O
tom,O
onset,O
between,O
3,NUMBER
‐,O
41,PERCENT
%,PERCENT
[,O
52,NUMBER
.,O
53,NUMBER
],O
.,O
Initial,O
sensitivity,O
of,O
RT,O
‐,O
PCR,O
to,O
identify,O
SARS,O
‐,O
CoV,O
‐,O
2,NUMBER
infected,O
patients,O
was,O
found,O
approximately,O
71,PERCENT
%,PERCENT
in,O
two,NUMBER
different,O
studies,O
[,O
54,NUMBER
.,O
55,NUMBER
],O
.,O
Meanwhile,O
positive,O
test,O
rates,O
were,O
found,O
to,O
be,O
lower,O
for,O
throat,O
samples,O
in,O
comparison,O
with,O
nasal,O
samples,O
(,O
24,PERCENT
%,PERCENT
Eurasian,O
J,O
Med,O
2020,DATE
;,O
52,NUMBER
(,O
2,NUMBER
),O
:,O
191,NUMBER
‐,O
6,NUMBER
vs.,O
57,PERCENT
%,PERCENT
respectively,O
),O
[,O
56,NUMBER
],O
.,O
Likelihood,O
of,O
positivity,O
reduces,O
with,O
time,O
past,DATE
after,O
initiation,O
of,O
symptoms,O
;,O
the,O
chance,O
of,O
a,O
positive,O
test,O
with,O
nasal,O
swab,O
declines,O
from,O
94.39,PERCENT
%,PERCENT
on,O
day,DURATION
0,NUMBER
to,O
67.15,PERCENT
%,PERCENT
by,O
day,DURATION
10,NUMBER
.,O
and,O
there,O
is,O
only,O
a,O
2.38,PERCENT
%,PERCENT
chance,O
of,O
a,O
positive,O
test,O
by,O
day,DURATION
31,NUMBER
.,O
(,O
positive,O
rates,O
for,O
throat,O
swabs,O
:,O
88,PERCENT
%,PERCENT
.,O
47.11,PERCENT
%,PERCENT
.,O
and,O
1.05,PERCENT
%,PERCENT
for,O
day,DURATION
0,NUMBER
.,O
10,NUMBER
and,O
31,NUMBER
respectively,O
),O
[,O
51,NUMBER
],O
.,O
Guidelines,O
from,O
the,O
WHO,O
and,O
the,O
European,ORGANIZATION
Centre,ORGANIZATION
for,ORGANIZATION
Disease,ORGANIZATION
Control,ORGANIZATION
noted,O
that,O
a,O
sole,O
nega,O
‐,O
tive,O
result,O
is,O
inadequate,O
to,O
exclude,O
disease,CAUSE_OF_DEATH
.,O
After,O
a,O
patient,O
has,O
had,O
a,O
positive,O
test,O
result,O
.,O
various,O
experts,O
have,O
advised,O
get,O
‐,O
ting,O
minimum,O
2,NUMBER
negative,O
upper,O
respiratory,O
tract,O
samples,O
.,O
obtained,O
at,O
periods,O
of,O
24,DURATION
hours,DURATION
or,O
longer,O
.,O
to,O
document,O
SARS,O
‐,O
CoV,O
‐,O
2,NUMBER
clear,O
‐,O
ance,O
[,O
57,NUMBER
.,O
58,NUMBER
],O
.,O
Compared,O
with,O
serial,O
nasopharyngeal,O
sampling,O
.,O
chest,O
computed,O
tomography,O
(,O
CT,STATE_OR_PROVINCE
),O
may,O
be,O
more,O
sensitive,O
than,O
an,O
RT,O
‐,O
PCR,O
test,O
at,O
a,O
single,O
time,O
point,O
for,O
the,O
diagnosis,O
of,O
COVID,O
‐,O
19,NUMBER
[,O
5254,NUMBER
],O
.,O
However,O
.,O
CT,STATE_OR_PROVINCE
findings,O
are,O
not,O
completely,O
specific,O
to,O
COVID,O
‐,O
19,NUMBER
and,O
do,O
not,O
exclude,O
a,O
coinfection,O
or,O
an,O
alternative,O
diag,O
‐,O
nosis,O
[,O
59,NUMBER
],O
.,O
Clinical,O
Course,O
COVID,O
‐,O
19,NUMBER
can,O
be,O
divided,O
into,O
three,NUMBER
different,O
clinical,O
stages,O
[,O
60,NUMBER
],O
:,O
Asymptomatic,O
stage,O
(,O
First,ORDINAL
1,NUMBER
‐,O
2,NUMBER
days,DURATION
),O
:,O
SARS,O
‐,O
CoV,O
‐,O
2,NUMBER
enters,O
upper,O
airways,O
and,O
binds,O
to,O
epithelial,O
cells,O
.,O
There,O
is,O
local,O
propagation,O
of,O
the,O
virus,O
despite,O
a,O
limited,O
innate,O
immune,O
response,O
.,O
Individuals,O
can,O
spread,O
infection,CAUSE_OF_DEATH
and,O
virus,O
can,O
be,O
detected,O
in,O
the,O
upper,O
airways,O
at,O
this,O
stage,O
.,O
Con,O
‐,O
ducting,O
airway,O
immune,O
response,O
(,O
Next,DATE
few,DATE
days,DATE
),O
:,O
The,O
virus,O
moves,O
down,O
through,O
airways,O
.,O
innate,O
immune,O
response,O
is,O
triggered,O
.,O
and,O
the,O
disease,CAUSE_OF_DEATH
clinically,O
manifest,O
.,O
Approximately,O
80,PERCENT
%,PERCENT
of,O
the,O
cases,O
.,O
the,O
disease,CAUSE_OF_DEATH
is,O
restricted,O
to,O
this,O
stage,O
and,O
clinical,O
course,O
will,O
be,O
mild,O
.,O
Respiratory,CAUSE_OF_DEATH
failure,CAUSE_OF_DEATH
and,O
progression,O
to,O
ARDS,O
:,O
About,O
20,PERCENT
%,PERCENT
of,O
the,O
patients,O
will,O
progress,O
to,O
stage,O
3,NUMBER
.,O
The,O
virus,O
reaches,O
the,O
gas,O
exchange,O
units,O
of,O
the,O
lung,O
and,O
develop,O
pulmonary,O
infiltrates,O
.,O
SARS,O
‐,O
CoV,O
‐,O
2,NUMBER
exhibited,O
neurotropic,O
features,O
.,O
cases,O
with,O
COVID,O
‐,O
19,NUMBER
may,O
have,O
neurological,O
manifestations,O
comprising,O
headache,O
.,O
altered,O
consciousness,O
.,O
and,O
paresthesia,O
[,O
61,NUMBER
],O
.,O
In,O
addition,O
.,O
increasing,O
num,O
‐,O
bers,O
of,O
cases,O
present,DATE
with,O
anosmia,O
[,O
62,NUMBER
],O
.,O
SARS,O
‐,O
CoV,O
‐,O
2,NUMBER
was,O
detected,O
in,O
the,O
brain,O
or,O
cerebrospinal,O
fluid,O
[,O
63,NUMBER
],O
.,O
Neuronal,O
degeneration,O
and,O
intracranial,O
edema,O
was,O
shown,O
in,O
autopsies,O
[,O
64,NUMBER
],O
.,O
Neurologic,O
involvement,O
of,O
coronaviruses,O
manifests,O
in,O
three,NUMBER
categories,O
:,O
Viral,O
encephalitis,O
.,O
infectious,O
toxic,O
encephalopathy,O
.,O
and,O
acute,O
cere,O
‐,O
brovascular,O
disease,CAUSE_OF_DEATH
[,O
65,NUMBER
],O
.,O
The,O
mechanism,O
of,O
neuroinvasion,O
is,O
still,O
unknown,O
.,O
Possible,O
pathways,O
are,O
proposed,O
:,O
1,NUMBER
.,O
Direct,O
infection,CAUSE_OF_DEATH
in,O
‐,O
jury,O
.,O
2,NUMBER
.,O
Hypoxia,O
injury,O
.,O
3,NUMBER
.,O
Immune,O
injury,O
.,O
4,NUMBER
.,O
ACE2,O
related,O
in,O
‐,O
jury,O
.,O
Use,O
of,O
Noninvasive,O
Mechanical,O
Ventilation,O
HFNO,O
can,O
be,O
used,O
in,O
COVID,O
‐,O
19,NUMBER
patients,O
.,O
but,O
infection,CAUSE_OF_DEATH
spread,O
is,O
a,O
real,O
concern,O
in,O
this,O
method,O
.,O
Spread,O
of,O
virus,O
may,O
reduce,O
with,O
putting,O
‐,O
on,O
a,O
surgi,O
‐,O
cal,O
mask,O
above,O
high,O
flow,O
nasal,O
cannula,O
.,O
CPAP,O
must,O
be,O
first,ORDINAL
choice,O
of,O
non,O
‐,O
invasive,O
ventilation,O
for,O
COVID,O
‐,O
19,NUMBER
patients,O
with,O
hy,O
‐,O
poxemic,O
respiratory,CAUSE_OF_DEATH
failure,CAUSE_OF_DEATH
.,O
CPAP,ORGANIZATION
response,O
must,O
be,O
assessed,O
with,O
‐,O
in,O
half,O
an,DURATION
hour,DURATION
.,O
and,O
unless,O
it,O
is,O
adequate,O
.,O
early,O
intubation,O
and,O
invasive,O
mechanical,O
ventilation,O
(,O
IMV,O
),O
should,O
be,O
applied,O
.,O
CPAP,O
must,O
be,O
continued,O
if,O
clinical,O
findings,O
of,O
the,O
patient,O
are,O
improv,O
‐,O
ing,O
.,O
and,O
a,O
trial,O
of,O
weaning,O
CPAP,MISC
should,O
be,O
considered,O
when,O
oxygen,O
concentration,O
<,O
40,PERCENT
%,PERCENT
[,O
66,NUMBER
],O
.,O
The,O
peripheral,O
oxygen,O
saturation,O
(,O
SpO2,O
),O
monitoring,O
is,O
generally,O
sufficient,O
[,O
66,NUMBER
],O
.,O
Arterial,O
blood,O
gas,O
mon,DATE
‐,O
itoring,O
is,O
not,O
necessary,O
unless,O
PaCO2,O
is,O
elevated,O
at,O
presenta,O
‐,O
tion,O
.,O
Target,O
level,O
of,O
SpO2,O
is,O
92,NUMBER
‐,O
96,PERCENT
%,PERCENT
.,O
and,O
for,O
patients,O
with,O
chronic,O
type,O
II,NUMBER
respiratory,CAUSE_OF_DEATH
failure,CAUSE_OF_DEATH
is,O
88,NUMBER
‐,O
92,PERCENT
%,PERCENT
[,O
66,NUMBER
],O
.,O
Bilevel,O
NIV,O
(,O
BiPAP,O
),O
should,O
be,O
considered,O
for,O
clinical,O
deteriorating,O
patients,O
despite,O
adequate,O
CPAP,O
support,O
or,O
for,O
patients,O
with,O
hypercapnic,O
respiratory,CAUSE_OF_DEATH
failure,CAUSE_OF_DEATH
.,O
Location,O
of,O
NIV,ORGANIZATION
treatment,O
is,O
an,O
important,O
issue,O
in,O
COVID,O
‐,O
19,NUMBER
pandemic,O
to,O
be,O
able,O
to,O
protect,O
the,O
healthcare,O
workers,O
(,O
HCWs,O
),O
because,O
of,O
the,O
high,O
spread,O
rate,O
of,O
the,O
disease,CAUSE_OF_DEATH
.,O
It,O
is,O
recommended,O
that,O
NIV,ORGANIZATION
is,O
delivered,O
in,O
a,O
negative,O
pressure,O
room,O
with,O
air,O
exchanges,O
greater,O
than,O
10,NUMBER
cycles,O
per,O
hour,DURATION
in,O
order,O
to,O
avoid,O
virus,O
spread,O
and,O
to,O
protect,O
HCWs,O
.,O
However,O
.,O
if,O
a,O
negative,O
pressure,O
room,O
is,O
not,O
available,O
because,O
of,O
insufficient,O
number,O
of,O
ICU,O
beds,O
.,O
respiratory,O
intermediate,O
units,O
with,O
opportunity,O
of,O
air,O
exchange,O
(,O
big,O
windows,O
that,O
can,O
be,O
opened,O
periodically,O
making,O
pos,O
‐,O
sible,O
to,O
change,O
air,O
at,O
least,O
at,O
a,O
rate,O
of,O
160L,O
/,O
h,O
),O
are,O
suggested,O
to,O
deliver,O
respiratory,O
support,O
to,O
entire,O
patients,O
[,O
67,NUMBER
],O
.,O
First,ORDINAL
recommended,O
interface,O
for,O
NIV,ORGANIZATION
is,O
a,O
full,O
‐,O
face,O
non,O
‐,O
vented,O
mask,O
with,O
expiratory,O
viral,O
filter,O
;,O
after,O
that,O
a,O
helmet,O
preferably,O
with,O
air,O
cushion,O
.,O
a,O
standard,O
face,O
mask,O
must,O
be,O
last,O
choice,O
.,O
A,O
viral,O
/,O
bacte,O
‐,O
rial,O
filter,O
should,O
be,O
placed,O
in,O
the,O
circuit,O
between,O
the,O
mask,O
and,O
the,O
oxygen,O
and,O
exhalation,O
ports,O
and,O
should,O
be,O
changed,O
every,O
24,NUMBER
hours,DURATION
.,O
An,O
external,O
humidifier,O
should,O
be,O
avoided,O
.,O
Contamination,O
risk,O
of,O
HCWs,O
during,O
NIV,O
is,O
supposed,O
to,O
be,O
low,O
when,O
staff,O
is,O
equipped,O
with,O
proper,O
personal,O
protective,O
equipments,O
which,O
are,O
a,O
FFP3,O
respirator,O
.,O
double,O
non,O
‐,O
sterile,O
gloves,O
.,O
long,O
‐,O
sleeved,O
water,O
‐,O
resistant,O
gown,O
.,O
goggles,O
or,O
face,O
shield,O
.,O
Anecdotal,O
observations,O
in,O
field,O
have,O
noted,O
that,O
patients,O
with,O
COVID,O
‐,O
19,NUMBER
‐,O
related,O
respira,O
‐,O
tory,O
failure,O
respond,O
well,O
to,O
prone,O
positioning,O
with,O
NIV,ORGANIZATION
.,O
espe,O
‐,O
cially,O
in,O
those,O
who,O
had,O
posterior,O
subplevral,O
dominant,O
opacities,O
in,O
their,O
lung,O
CT,O
.,O
The,O
Yuksel,PERSON
et,O
al,O
.,O
The,O
Unknowns,O
of,O
COVID,O
‐,O
19,NUMBER
Eurasian,MISC
J,O
Med,O
2020,DATE
;,O
52,NUMBER
(,O
2,NUMBER
),O
:,O
191,NUMBER
‐,O
6,NUMBER
care,O
should,O
be,O
taken,O
to,O
avoid,O
ventilator,TITLE
disconnections,O
during,O
proning,O
and,O
the,O
number,O
of,O
staff,O
should,O
be,O
minimalized,O
for,O
turning,O
.,O
Optimal,O
timing,O
and,O
criteria,O
for,O
prone,O
ventilation,O
with,O
NIV,ORGANIZATION
is,O
unclear,O
and,O
should,O
be,O
performed,O
on,O
an,O
individualized,O
basis,O
.,O
Use,O
of,O
Steroids,O
.,O
Nonsteroidal,O
Anti,O
‐,O
inflammatory,O
Drugs,CRIMINAL_CHARGE
.,O
and,O
Vitamin,ORGANIZATION
C,ORGANIZATION
Current,ORGANIZATION
WHO,ORGANIZATION
recommendations,O
ad,O
‐,O
vise,O
against,O
routine,O
use,O
of,O
prednisolone,O
in,O
the,O
management,O
of,O
COVID,O
‐,O
19,NUMBER
[,O
1,NUMBER
],O
.,O
Corticosteroids,O
have,O
shown,O
to,O
be,O
failed,O
against,O
respiratory,O
tract,O
viruses,O
including,O
MERS,O
.,O
SARS,O
.,O
and,O
influenza,CAUSE_OF_DEATH
in,O
various,O
studies,O
.,O
and,O
have,O
serious,O
adverse,O
effects,O
including,O
psy,O
‐,O
chosis,O
.,O
diabetes,CAUSE_OF_DEATH
.,O
avascular,O
necrosis,O
.,O
Corticosteroid,O
which,O
can,O
repress,O
cell,O
‐,O
mediated,O
immunity,O
.,O
stimulate,O
the,O
reduction,O
of,O
T,O
lym,O
‐,O
phocyte,O
.,O
and,O
postpone,O
the,O
virus,O
clearance,O
[,O
68,NUMBER
],O
.,O
may,O
worsen,O
the,O
defective,O
function,O
of,O
lymphocytes,O
in,O
patients,O
with,O
SARSCoV,O
‐,O
2,NUMBER
.,O
However,O
.,O
a,O
retrospective,O
study,O
reported,O
that,O
application,O
of,O
steroids,O
was,O
attributed,O
to,O
decreased,O
mortality,O
in,O
patients,O
with,O
COVID,O
‐,O
19,NUMBER
associated,O
ARDS,ORGANIZATION
[,O
69,NUMBER
],O
.,O
Hence,O
.,O
the,O
use,O
of,O
corticosteroids,O
should,O
be,O
careful,O
in,O
severe,O
patients,O
with,O
COVID,O
‐,O
19,NUMBER
pneumonia,CAUSE_OF_DEATH
.,O
and,O
the,O
time,O
of,O
corticosteroid,O
prescription,O
merit,O
additional,O
investi,O
‐,O
gation,O
.,O
Although,O
the,O
use,O
of,O
NSAIDs,MISC
in,O
COVID,O
‐,O
19,NUMBER
has,O
also,O
been,O
a,O
controversial,O
issue,O
.,O
it,O
was,O
clarified,O
by,O
WHO,O
that,O
avoiding,O
NSAIDs,O
was,O
not,O
recommended,O
since,O
it,O
was,O
not,O
associated,O
with,O
worse,O
prog,O
‐,O
nosis,O
as,O
previously,DATE
claimed,O
[,O
1,NUMBER
],O
.,O
Vitamin,O
C,O
has,O
been,O
suggested,O
as,O
a,O
therapeutic,O
option,O
for,O
COVID,O
‐,O
19,NUMBER
based,O
on,O
a,O
prospective,O
random,O
‐,O
ized,O
trial,O
of,O
intravenous,O
vitamin,O
C,O
in,O
patients,O
with,O
sepsis,CAUSE_OF_DEATH
and,O
ARDS,ORGANIZATION
[,O
70,NUMBER
],O
.,O
In,O
that,O
trial,O
.,O
there,O
was,O
no,O
difference,O
in,O
the,O
sequen,O
‐,O
tial,O
organ,O
failure,O
assessment,O
(,O
SOFA,O
),O
score,O
and,O
28,NUMBER
‐,O
day,DURATION
mortality,O
between,O
the,O
vitamin,O
C,O
and,O
placebo,O
groups,O
.,O
There,O
is,O
no,O
evidence,O
to,O
support,O
use,O
of,O
vitamin,O
C,O
in,O
patients,O
with,O
SARS,O
‐,O
CoV,O
‐,O
2,NUMBER
infection,CAUSE_OF_DEATH
.,O
however,O
there,O
is,O
an,O
ongoing,O
clinical,O
trial,O
for,O
high,O
‐,O
dose,O
vitamin,O
C,O
in,O
China,COUNTRY
(,O
NCT04264533,O
),O
.,O
Despite,O
significant,O
progresses,O
achieved,O
globally,O
in,O
the,O
struggle,O
with,O
the,O
COVID,O
‐,O
19,NUMBER
pandemic,O
;,O
there,O
are,O
still,O
many,O
conflicting,O
and,O
unclear,O
issues,O
particularly,O
regarding,O
pathogenesis,O
.,O
clinical,O
course,O
.,O
diagnosis,O
and,O
treatment,O
strategies,O
.,O
Further,O
studies,O
are,O
required,O
to,O
elucidate,O
these,O
challenging,O
issues,O
.,O
thus,O
to,O
enhance,O
the,O
management,O
of,O
COVID,O
‐,O
19,NUMBER
patients,O
.,O
‐,O
A.Y.,O
.,O
D.K.,O
;,O
Supervision,O
‐,O
A.Y.,O
.,O
D.K.,LOCATION
.,O
M.A.,O
;,O
Re,O
‐,O
sources,O
A.Y.,PERSON
.,O
F.T.A.,O
.,O
F.M.,O
;,O
Materials,O
‐,O
A.Y.,O
.,O
D.K.,O
.,O
C.G.G.,O
.,O
Z.N.T.,O
.,O
I.S.,O
;,O
Data,O
Collection,O
and,O
/,O
or,O
Processing,O
‐,O
A.Y.,O
.,O
D.K.,LOCATION
.,O
T.S.E.,O
.,O
N.E.,LOCATION
.,O
E.D.,LOCATION
.,O
S.C.,STATE_OR_PROVINCE
.,O
U.O.S.,LOCATION
.,O
T.R.G.,O
.,O
M.F.E.,O
.,O
A.O.,O
.,O
B.E.,O
.,O
A.F.,PERSON
.,O
F.E.G.,O
.,O
H.O.,O
.,O
N.O.,O
.,O
D.E.,LOCATION
.,O
A.A.,LOCATION
.,O
N.K.,LOCATION
.,O
M.E.,O
.,O
P.Y.G.,O
.,O
E.Y.,O
.,O
I.I.,PERSON
.,O
B.Y.K.,LOCATION
.,O
S.G.,LOCATION
;,O
Analysis,O
and,O
/,O
or,O
Interpretation,O
‐,O
A.Y.,O
.,O
D.K.,O
;,O
Literature,O
Search,O
‐,O
A.Y.,O
.,O
D.K.,LOCATION
.,O
C.G.G.,O
.,O
Z.N.T.,O
.,O
I.S.,O
.,O
T.S.E.,O
.,O
N.E.,LOCATION
.,O
E.D.,LOCATION
.,O
S.C.,STATE_OR_PROVINCE
.,O
U.O.S.,LOCATION
.,O
T.R.G.,O
.,O
M.F.E.,O
.,O
A.O.,O
.,O
B.E.,LOCATION
.,O
A.F.,O
.,O
F.E.G.,O
.,O
H.O.,O
.,O
N.O.,O
.,O
D.E.,LOCATION
.,O
A.A.,LOCATION
.,O
N.K.,LOCATION
.,O
M.E.,O
.,O
P.Y.G.,O
.,O
E.Y.,O
.,O
Ac,O
‐,O
knowledgements,O
:,O
This,O
study,O
was,O
supported,O
by,O
Turkish,NATIONALITY
Thoracic,O
So,O
‐,O
ciety,O
(,O
TTS,O
),O
and,O
is,O
a,O
product,O
of,O
the,O
collaboration,O
of,O
TTS,O
Early,O
Career,ORGANIZATION
Members,ORGANIZATION
Taskforce,ORGANIZATION
Group,ORGANIZATION
.,O
interest,O
to,O
declare,O
.,O
study,O
has,O
received,O
no,O
financial,O
support,O
.,O
WHO,O
‐,O
Clinical,O
management,O
of,O
se,O
‐,O
vere,O
acute,O
respiratory,CAUSE_OF_DEATH
infection,CAUSE_OF_DEATH
(,O
SARI,O
),O
when,O
COVID,O
‐,O
19,NUMBER
disease,CAUSE_OF_DEATH
is,O
suspected,O
:,O
Interim,O
guidance,O
.,O
Available,O
2,NUMBER
.,O
Gupta,PERSON
N,O
.,O
Zhao,PERSON
YY,PERSON
.,O
Evans,PERSON
CE,O
.,O
The,O
stimulation,O
of,O
thrombosis,CAUSE_OF_DEATH
by,O
hypoxia,O
.,O
Thromb,O
Res,O
2019,DATE
;,O
181,NUMBER
:,O
3,NUMBER
.,O
Luo,PERSON
W,PERSON
.,O
Yu,PERSON
H,PERSON
.,O
Gou,PERSON
J,PERSON
.,O
et,O
al,O
.,O
Clinical,O
Pathology,O
of,O
Critical,O
Patient,O
with,O
Novel,O
Coronavirus,O
Pneumonia,CAUSE_OF_DEATH
(,O
COVID,O
‐,O
19,NUMBER
),O
.,O
Preprints,O
2020,DATE
;,O
2020020407,NUMBER
.,O
4,NUMBER
.,O
Wrapp,O
D,O
.,O
Wang,PERSON
N,PERSON
.,O
Corbett,ORGANIZATION
KS,ORGANIZATION
.,O
et,O
al,O
.,O
Cryo,O
‐,O
EM,O
structure,O
of,O
the,O
2019,DATE
‐,O
nCoV,O
spike,O
in,O
the,O
prefusion,O
conformation,O
.,O
Science,O
2020,DATE
;,O
367,NUMBER
:,O
1260,DATE
‐,O
3,NUMBER
.,O
5,NUMBER
.,O
Dutta,PERSON
M,O
.,O
Dutta,PERSON
P,PERSON
.,O
Medhi,PERSON
S,PERSON
.,O
Borkakoty,O
B,O
.,O
Biswas,PERSON
D.,O
Polymorphism,O
of,O
HLA,O
class,O
I,NUMBER
and,O
class,O
II,NUMBER
alleles,O
in,O
influenza,CAUSE_OF_DEATH
A,O
(,O
H1N1,O
),O
pdm09,O
virus,O
infected,O
population,O
of,O
Assam,LOCATION
.,O
Northeast,LOCATION
India,COUNTRY
.,O
J,O
Med,O
Virol,O
2018,DATE
;,O
90,NUMBER
:,O
854,NUMBER
‐,O
60,NUMBER
.,O
[,O
Crossref,O
],O
6,NUMBER
.,O
Shi,O
Y,O
.,O
Wang,O
Y,O
.,O
Shao,PERSON
C,PERSON
.,O
et,O
al,O
.,O
Cell,O
Death,O
Differ,O
.,O
COVID,O
‐,O
19,NUMBER
in,O
‐,O
fection,O
:,O
the,O
perspectives,O
on,O
immune,O
responses,O
.,O
Cell,O
Death,O
Differ,O
2020,DATE
;,O
27,NUMBER
:,O
7,NUMBER
.,O
Guan,O
W,O
.,O
Ni,MISC
Z,O
.,O
Hu,O
Y,O
et,O
al,O
.,O
Clinical,O
Characteristics,O
of,O
Coronavirus,O
Disease,CAUSE_OF_DEATH
2019,DATE
in,O
China,COUNTRY
.,O
N,O
Engl,O
J,O
Med,O
2020,DATE
;,O
382,NUMBER
:,O
1708,DATE
‐,O
20,NUMBER
.,O
[,O
Crossref,O
],O
8,NUMBER
.,O
Huang,PERSON
C,PERSON
.,O
Wang,O
Y,O
.,O
Li,PERSON
X,PERSON
.,O
et,O
al,O
.,O
Clinical,O
features,O
of,O
patients,O
infected,O
with,O
2019,DATE
novel,O
coronavirus,O
in,O
Wuhan,CITY
.,O
China,COUNTRY
.,O
Lancet,O
2020,DATE
;,O
395,NUMBER
:,O
497,NUMBER
‐,O
506,NUMBER
.,O
9,NUMBER
.,O
Wang,PERSON
D,PERSON
.,O
Hu,O
B,O
.,O
Hu,O
C,O
.,O
et,O
al,O
.,O
Clinical,O
Characteristics,O
of,O
138,NUMBER
Hospitalized,O
Patients,O
With,O
2019,DATE
Novel,MISC
Coronavirus,MISC
‐,MISC
Infected,MISC
Pneumonia,CAUSE_OF_DEATH
in,O
Wuhan,CITY
.,O
China,COUNTRY
.,O
JAMA,PERSON
2020,DATE
;,O
323,NUMBER
:,O
1061,DATE
‐,O
9,NUMBER
.,O
[,O
Crossref,O
],O
10,NUMBER
.,O
Qin,PERSON
C,O
.,O
Zhou,PERSON
L,PERSON
.,O
Hu,O
Z,O
.,O
et,O
al,O
.,O
Dysregulation,O
of,O
immune,O
response,O
in,O
patients,O
with,O
COVID,O
‐,O
19,DATE
11,DATE
.,O
He,O
R,O
.,O
Lu,PERSON
Z,PERSON
.,O
Zhang,PERSON
L,PERSON
.,O
et,O
al,O
.,O
The,O
clinical,O
course,O
and,O
its,O
correlated,O
immune,O
status,O
in,O
COVID,O
‐,O
19,NUMBER
pneumonia,CAUSE_OF_DEATH
.,O
J,PERSON
Clin,PERSON
Virol,PERSON
2020,DATE
;,O
127,NUMBER
:,O
104361,NUMBER
.,O
12,NUMBER
.,O
Chu,PERSON
H,PERSON
.,O
Zhou,PERSON
J,PERSON
.,O
Wong,PERSON
BH,O
‐,O
Y,O
.,O
et,O
al,O
.,O
Middle,O
East,O
Respi,O
‐,O
ratory,O
Syndrome,O
Coronavirus,O
Efficiently,O
Infects,O
Human,O
Primary,O
T,O
Lymphocytes,O
and,O
Activates,MISC
the,MISC
Extrinsic,MISC
and,O
Intrinsic,O
Apoptosis,O
Pathways,O
.,O
J,O
Infect,O
Dis,O
2015,DATE
;,O
213,NUMBER
:,O
904,NUMBER
‐,O
14,NUMBER
.,O
[,O
Crossref,O
],O
13,NUMBER
.,O
Yoshikawa,PERSON
T,O
.,O
Hill,PERSON
T,PERSON
.,O
Li,PERSON
K,PERSON
.,O
Peters,ORGANIZATION
CJ,ORGANIZATION
.,O
Tseng,PERSON
C,O
‐,O
TK,O
.,O
Severe,O
Acute,O
Respiratory,O
Syndrome,O
(,O
SARS,O
),O
Coronavirus,O
‐,O
Induced,O
Lung,O
Epithelial,O
Cytokines,O
Exacerbate,O
SARS,O
Pathogenesis,O
by,O
Modulating,O
Intrinsic,O
Functions,O
of,O
Monocyte,O
‐,O
Derived,O
Macrophages,O
and,O
Dendritic,O
Cells,O
.,O
J,O
Virol,O
2009,DATE
;,O
83,NUMBER
:,O
14,NUMBER
.,O
Zhao,PERSON
J,PERSON
.,O
Zhao,PERSON
J,PERSON
.,O
Van,PERSON
Rooijen,PERSON
N,O
.,O
Perlman,PERSON
S.,PERSON
Evasion,O
by,O
Stealth,O
:,O
Inefficient,O
Immune,O
Activation,O
Underlies,O
Poor,O
T,O
Cell,O
Response,O
and,O
Severe,O
Disease,CAUSE_OF_DEATH
in,O
SARS,O
‐,O
CoV,O
‐,O
Infected,O
Mice,O
.,O
Gale,O
M,O
.,O
ed,O
.,O
PLoS,O
Pathog,O
2009,DATE
;,O
5,NUMBER
:,O
e1000636,O
.,O
[,O
Crossref,O
],O
15,NUMBER
.,O
Khanahmad,PERSON
H,PERSON
.,O
Kouhpayeh,PERSON
S,PERSON
.,O
Rahimmanes,O
I,O
.,O
The,O
conceptual,O
framework,O
for,O
SARS,O
‐,O
CoV,O
‐,O
2,NUMBER
16,NUMBER
.,O
Gralinski,PERSON
LE,PERSON
.,O
Sheahan,PERSON
TP,O
.,O
Morrison,ORGANIZATION
TE,ORGANIZATION
.,O
et,O
al,O
.,O
Complement,O
Activation,O
Contributes,O
to,O
Severe,O
Acute,O
Respiratory,O
Syndrome,O
Coronavirus,O
Pathogenesis,O
.,O
mBio,O
2018,DATE
;,O
9,NUMBER
:,O
e01753,NUMBER
‐,O
18,NUMBER
.,O
[,O
Crossref,O
],O
17,NUMBER
.,O
Xu,PERSON
Z,PERSON
.,O
Shi,PERSON
L,PERSON
.,O
Wang,O
Y,O
.,O
et,O
al,O
.,O
Pathological,O
findings,O
of,O
COVID,O
‐,O
19,NUMBER
associated,O
with,O
acute,O
respiratory,O
distress,O
syndrome,O
.,O
Lancet,O
Respir,O
Med,O
2020,DATE
;,O
8,NUMBER
:,O
18,NUMBER
.,O
Bell,ORGANIZATION
TJ,ORGANIZATION
.,O
Brand,ORGANIZATION
OJ,ORGANIZATION
.,O
Morgan,ORGANIZATION
DJ,ORGANIZATION
.,O
et,O
al,O
.,O
Defective,O
lung,O
function,O
following,O
influenza,CAUSE_OF_DEATH
virus,O
is,O
due,O
to,O
prolonged,O
.,O
reversible,O
hyaluronan,O
synthesis,O
.,O
Matrix,O
Biol,O
2018,DATE
;,O
80,NUMBER
:,O
14,NUMBER
‐,O
28,NUMBER
.,O
[,O
Crossref,O
],O
19,NUMBER
.,O
Chen,O
N,O
.,O
Zhou,PERSON
M,O
.,O
Dong,PERSON
X,PERSON
et,O
al,O
.,O
Epidemiologi,O
‐,O
cal,O
and,O
clinical,O
characteristics,O
of,O
99,NUMBER
cases,O
of,O
2019,DATE
novel,O
coron,O
‐,O
avirus,O
pneumonia,CAUSE_OF_DEATH
in,O
Wuhan,CITY
.,O
China,COUNTRY
:,O
a,O
descriptive,O
study,O
.,O
Lancet,O
2020,DATE
;,O
395,NUMBER
:,O
507,NUMBER
‐,O
13,NUMBER
.,O
20,NUMBER
.,O
Wenzhong,PERSON
L,PERSON
.,O
Hualan,PERSON
L.,PERSON
COVID,PERSON
‐,O
19,NUMBER
:,O
Attacks,CAUSE_OF_DEATH
the,O
1,NUMBER
‐,O
Beta,O
Chain,O
of,O
Hemoglobin,O
and,O
Captures,O
the,O
Porphyrin,O
to,O
In,O
‐,O
hibit,O
Human,O
Heme,O
Metabolism,O
.,O
21,NUMBER
.,O
Zhou,PERSON
F,PERSON
.,O
Yu,PERSON
T,PERSON
.,O
Du,PERSON
R,PERSON
.,O
et,O
al,O
.,O
Clinical,O
course,O
and,O
risk,O
factors,O
for,O
mortality,O
of,O
adult,O
inpa,O
‐,O
tients,O
with,O
COVID,O
‐,O
19,NUMBER
in,O
Wuhan,CITY
.,O
China,COUNTRY
:,O
a,O
retrospective,O
cohort,O
study,O
.,O
Lancet,O
2020,DATE
;,O
395,NUMBER
:,O
1054,DATE
‐,O
62,NUMBER
.,O
[,O
Crossref,O
],O
22,NUMBER
.,O
Gralinski,PERSON
LE,PERSON
.,O
Bankhead,PERSON
A,O
3rd,ORDINAL
.,O
Jeng,PERSON
S,PERSON
.,O
et,O
al,O
.,O
Mechanisms,O
of,O
severe,O
acute,O
respi,O
‐,O
ratory,O
syndrome,O
coronavirus,O
‐,O
induced,O
acute,O
lung,O
injury,O
.,O
mBio,O
2013,DATE
;,O
4,NUMBER
:,O
e00271,NUMBER
‐,O
e313,NUMBER
.,O
[,O
Crossref,O
],O
23,NUMBER
.,O
Berri,PERSON
F,O
.,O
Rimmelzwaan,PERSON
GF,PERSON
.,O
Hanss,O
M,O
.,O
et,O
al,O
.,O
Plasminogen,O
controls,O
inflammation,O
and,O
pathogenesis,O
of,O
in,O
‐,O
fluenza,O
virus,O
infections,CAUSE_OF_DEATH
via,O
fibrinolysis,O
.,O
PLoS,O
Pathog,O
2013,DATE
;,O
9,NUMBER
:,O
e1003229,O
.,O
[,O
Crossref,O
],O
24,NUMBER
.,O
Hana,PERSON
H,PERSON
.,O
Yanga,CITY
L,O
.,O
Liu,PERSON
R,PERSON
.,O
et,O
al,O
.,O
Prominent,O
changes,O
25,NUMBER
.,O
Yin,PERSON
S,PERSON
.,O
Huang,PERSON
M,O
.,O
Li,PERSON
D,PERSON
.,O
Tang,PERSON
N.,PERSON
Difference,PERSON
of,O
coagula,O
‐,O
tion,O
features,O
between,O
severe,O
pneumonia,CAUSE_OF_DEATH
induced,O
by,O
SARS,O
‐,O
CoV2,O
and,O
non,O
‐,O
SARS,O
‐,O
CoV2,O
.,O
J,O
Thromb,O
Thrombolysis,O
2020,DATE
;,O
1,NUMBER
‐,O
4,NUMBER
.,O
[,O
Crossref,O
],O
26,NUMBER
.,O
Tang,O
N,O
.,O
Li,PERSON
D,PERSON
.,O
Wang,PERSON
X,PERSON
.,O
Sun,O
Z.,O
Abnormal,O
coagulation,O
parameters,O
are,O
associated,O
with,O
poor,O
prognosis,O
in,O
patients,O
with,O
novel,O
coronavirus,O
196,NUMBER
Yuksel,PERSON
et,O
al,O
.,O
The,O
Unknowns,O
of,O
COVID,O
‐,O
19,NUMBER
pneumonia,CAUSE_OF_DEATH
.,O
J,PERSON
Thromb,PERSON
Haemost,O
2020,DATE
;,O
18,NUMBER
:,O
844,NUMBER
‐,O
7,NUMBER
.,O
Cui,PERSON
S,PERSON
.,O
Chen,PERSON
S,PERSON
.,O
L,O
X,O
.,O
Liu,PERSON
S,O
.,O
Wang,PERSON
F.,PERSON
Prevalence,O
of,O
venous,O
thromboembolism,O
in,O
patients,O
with,O
severe,O
nov,DATE
‐,O
el,O
coronavirus,O
pneumonia,CAUSE_OF_DEATH
.,O
J,PERSON
Thromb,PERSON
Zhang,PERSON
T,PERSON
.,O
Xiao,PERSON
M,O
.,O
Zhang,PERSON
S,PERSON
.,O
et,O
al,O
.,O
Coagulopathy,O
and,O
Antiphospholipid,O
Antibodies,O
in,O
Patients,O
with,O
Covid,O
‐,O
19,NUMBER
.,O
N,O
Engl,O
J,O
Med,O
2020,DATE
;,O
382,NUMBER
:,O
e38,O
.,O
Fox,O
SE,O
.,O
Akmatbekov,PERSON
A,O
.,O
Harbert,PERSON
JL,O
.,O
Li,PERSON
G,PERSON
.,O
Brown,PERSON
JQ,PERSON
.,O
Vander,PERSON
Heide,PERSON
RS,O
.,O
Pulmonary,O
and,O
Car,O
‐,O
diac,O
Iba,O
T,O
.,O
Levy,ORGANIZATION
JH,ORGANIZATION
.,O
Warkentin,ORGANIZATION
TE,ORGANIZATION
.,O
et,O
al,O
.,O
Diagnosis,O
and,O
manage,O
‐,O
ment,O
of,O
sepsis,CAUSE_OF_DEATH
‐,O
induced,O
coagulopathy,O
and,O
disseminated,O
intravascu,O
‐,O
lar,O
coagulation,O
.,O
J,O
Thromb,O
Haemost,O
2019,DATE
;,O
17,NUMBER
:,O
1989,DATE
‐,O
94,NUMBER
.,O
[,O
Crossref,O
],O
Tang,O
N,O
.,O
Bai,PERSON
H,O
.,O
Chen,PERSON
X,PERSON
.,O
Gong,O
J,O
.,O
Li,PERSON
D,PERSON
.,O
Sun,PERSON
Z.,PERSON
Anticoagulant,PERSON
treat,O
‐,O
ment,O
is,O
associated,O
with,O
decreased,O
mortality,O
in,O
severe,O
coronavirus,O
disease,CAUSE_OF_DEATH
2019,DATE
patients,O
with,O
coagulopathy,O
.,O
J,PERSON
Thromb,PERSON
Haemost,PERSON
Liu,PERSON
X,PERSON
.,O
Li,PERSON
Z,PERSON
.,O
Liu,PERSON
S,O
et,O
al,O
.,O
Therapeutic,O
effects,O
of,O
Li,O
Q,O
.,O
Guan,O
X,O
.,O
Wu,PERSON
P,O
.,O
et,O
al,O
.,O
Early,O
transmission,O
dynamics,O
in,O
Wuhan,CITY
.,O
China,COUNTRY
.,O
of,O
novel,O
coron,O
‐,O
avirusinfected,O
pneumonia,CAUSE_OF_DEATH
.,O
N,O
Engl,O
J,O
Med,O
2020,DATE
;,O
382,NUMBER
:,O
Mizumoto,PERSON
K,PERSON
.,O
Ka,O
‐,O
gaya,O
K,O
.,O
Chowell,PERSON
G.,PERSON
Early,PERSON
epidemiological,O
assessment,O
of,O
the,O
trans,O
‐,O
mission,O
potential,O
and,O
virulence,O
of,O
coronavirus,O
disease,CAUSE_OF_DEATH
2019,DATE
(,O
COVID,O
‐,O
19,NUMBER
),O
in,O
Wuhan,CITY
City,LOCATION
:,O
China,COUNTRY
.,O
January,DATE
‐,O
February,DATE
.,O
Bai,PERSON
Y,PERSON
.,O
Yao,PERSON
L,PERSON
.,O
Wei,PERSON
T,PERSON
.,O
et,O
al,O
.,O
Presumed,O
asymptomatic,O
carrier,O
transmission,O
of,O
COVID,O
‐,O
19,NUMBER
.,O
JAMA,O
2020,DATE
;,O
Li,PERSON
R,PERSON
.,O
Pei,PERSON
S,O
.,O
Chen,PERSON
B,PERSON
.,O
et,O
al,O
.,O
Substantial,O
un,O
‐,O
documented,O
infection,CAUSE_OF_DEATH
facilitates,O
the,O
rapid,O
dissemination,O
of,O
novel,O
coronavirus,O
(,O
SARS,O
‐,O
CoV2,O
),O
.,O
Science,O
Liu,PERSON
EY,PERSON
.,O
Yan,PERSON
L,PERSON
.,O
Wan,O
L,O
.,O
et,O
al,O
.,O
Vi,PERSON
‐,O
ral,O
dynamics,O
in,O
mild,O
and,O
severe,O
cases,O
of,O
COVID,O
‐,O
19,NUMBER
.,O
Lancet,O
Infect,O
Dis,PERSON
Asadi,PERSON
S,PERSON
.,O
Wexler,PERSON
AS,STATE_OR_PROVINCE
.,O
Cappa,PERSON
CD,O
.,O
Barreda,PERSON
S,O
.,O
Bouvier,ORGANIZATION
NM,ORGANIZATION
.,O
Risten,O
‐,O
part,O
WD,O
.,O
Aerosol,O
emission,O
and,O
superemission,O
during,O
human,O
speech,O
increase,O
with,O
voice,O
loudness,O
.,O
Sci,MISC
Rep,TITLE
2019,DATE
;,O
9,NUMBER
:,O
2348,DATE
.,O
[,O
Crossref,O
],O
Ong,O
SWX,O
.,O
Tan,O
YK,O
.,O
Chia,PERSON
PY,PERSON
.,O
et,O
al,O
.,O
Air,O
.,O
surface,O
environmental,O
.,O
and,O
personal,O
protective,O
equipment,O
contamination,O
by,O
severe,O
acute,O
res,O
‐,O
piratory,O
syndrome,O
coronavirus,O
2,NUMBER
(,O
SARS,O
‐,O
CoV,O
‐,O
2,NUMBER
),O
from,O
a,O
symptomatic,O
patient,O
.,O
JAMA,O
2020,DATE
;,O
23,NUMBER
:,O
1610,DATE
‐,O
2,NUMBER
.,O
[,O
Crossref,O
],O
Wei,O
WE,O
.,O
Li,PERSON
Z,PERSON
.,O
Chiew,PERSON
CJ,O
.,O
Yong,PERSON
SE,PERSON
.,O
Toh,PERSON
MP,O
.,O
Lee,PERSON
VJ,O
.,O
Presymptomatic,O
Transmission,O
of,O
SARSCoV,O
‐,O
2,NUMBER
‐,O
Singapore,COUNTRY
.,O
January,DATE
23,DATE
‐,O
March,DATE
16,DATE
.,DATE
2020,DATE
.,O
MMWR,O
Morb,O
Mor,O
‐,O
tal,O
Wkly,O
Rep,TITLE
2020,DATE
;,O
69,NUMBER
:,O
4115,DATE
.,O
[,O
Crossref,O
],O
Bannister,PERSON
‐,O
Tyrrell,O
M,O
.,O
Mey,PERSON
‐,PERSON
er,O
A,O
.,O
Faverjon,O
C,O
.,O
et,O
al,O
.,O
Preliminary,O
evidence,O
that,O
higher,O
tem,O
‐,O
peratures,O
are,O
associated,O
with,O
lower,O
incidence,O
of,O
COVID,O
‐,O
19,NUMBER
.,O
Eurasian,MISC
J,O
Med,O
2020,DATE
;,O
52,NUMBER
(,O
2,NUMBER
),O
:,O
191,NUMBER
‐,O
6,NUMBER
for,O
cases,O
reported,O
globally,O
up,O
to,O
29th,DATE
February,DATE
Yao,O
Y,O
.,O
Pan,PERSON
J,PERSON
.,O
Liu,PERSON
Z,PERSON
.,O
et,O
al,O
.,O
No,O
Association,O
of,O
COVID,O
‐,O
19,NUMBER
transmission,O
with,O
temperature,O
or,O
UV,O
radiation,O
in,O
Chinese,NATIONALITY
cities,O
.,O
Eur,O
Respir,O
J,O
2020,DATE
;,O
55,NUMBER
:,O
Miller,PERSON
A,O
.,O
Reandelar,ORGANIZATION
MJ,ORGANIZATION
.,O
Fas,O
‐,O
ciglione,O
K,O
.,O
et,O
al,O
.,O
Correlation,O
between,O
universal,O
BCG,O
vaccination,O
policy,O
and,O
reduced,O
morbidity,O
and,O
mortality,O
for,O
COVID,O
‐,O
19,NUMBER
:,O
an,O
epi,O
‐,O
demiological,O
study,O
.,O
medRxiv,O
Onder,O
G,O
.,O
Rezza,PERSON
G,PERSON
.,O
Brusaferro,O
S.,O
Case,O
‐,O
fatality,O
Wilson,PERSON
N,O
.,O
Kvalsvig,PERSON
A,O
.,O
Barnard,ORGANIZATION
LT,ORGANIZATION
.,O
et,O
al,O
.,O
Casefatality,PERSON
risk,O
estimates,O
for,O
COVID,O
‐,O
19,NUMBER
calculated,O
by,O
using,O
a,O
lag,O
time,O
for,O
fatality,O
.,O
Emerg,O
Infect,O
Dis,PERSON
Dong,PERSON
E,PERSON
.,O
Du,PERSON
H,PERSON
.,O
Gardner,PERSON
L,O
.,O
An,O
interac,O
‐,O
tive,O
webbased,O
dashboard,O
to,O
track,O
COVID,O
‐,O
19,NUMBER
in,O
real,O
time,O
[,O
Letter,O
],O
.,O
Lancet,O
Infect,O
Dis,O
2020,DATE
;,O
20,NUMBER
:,O
533,NUMBER
‐,O
4,NUMBER
.,O
Cheng,PERSON
MP,O
.,O
Papenburg,PERSON
J,PERSON
.,O
Des,O
‐,O
jardins,O
M,O
.,O
et,O
al,O
.,O
Diagnostic,O
Testing,O
for,O
Severe,O
Acute,O
Respiratory,O
Syndrome,O
‐,O
Related,O
Coronavirus,O
‐,O
2,NUMBER
:,O
A,O
Narrative,O
Centers,O
for,O
Disease,CAUSE_OF_DEATH
Control,O
and,O
Prevention,O
.,O
Evaluating,O
and,O
Testing,O
Persons,O
for,O
Coro,O
‐,O
navirus,O
Disease,CAUSE_OF_DEATH
2019,DATE
(,O
COVID,O
‐,O
19,NUMBER
),O
.,O
Available,O
from,O
:,O
Wang,PERSON
W,PERSON
.,O
Xu,O
Y,O
.,O
Gao,PERSON
R,PERSON
.,O
et,O
al,O
.,O
Detection,O
of,O
SARSCoV,O
‐,O
2,NUMBER
in,O
different,O
types,O
of,O
clini,O
‐,O
cal,O
specimens,O
.,O
JAMA,O
2020,DATE
;,O
323,NUMBER
:,O
1843,DATE
‐,O
4,NUMBER
.,O
[,O
Crossref,O
],O
Wikramaratna,PERSON
P,O
.,O
Paton,PERSON
RS,O
.,O
Ghafari,PERSON
M,O
.,O
Loureno,O
J.,O
Estimating,O
false,O
‐,O
negative,O
de,O
‐,O
tection,O
rate,O
of,O
Xie,PERSON
X,PERSON
.,O
Zhong,PERSON
Z,PERSON
.,O
Zhao,PERSON
W,PERSON
.,O
Zheng,PERSON
C,PERSON
.,O
Wang,PERSON
F,PERSON
.,O
Liu,PERSON
J.,PERSON
Chest,O
CT,STATE_OR_PROVINCE
for,O
Typical,O
2019,DATE
‐,O
nCoV,O
Pneumonia,CAUSE_OF_DEATH
:,O
Relationship,O
to,O
Nega,O
‐,O
tive,O
RT,O
‐,O
PCR,O
Testing,O
.,O
Radiology,O
2020,DATE
;,O
200343,NUMBER
.,O
[,O
Crossref,O
],O
Ai,O
T,O
.,O
Yang,O
Z,O
.,O
Hou,PERSON
H,PERSON
.,O
et,O
al,O
.,O
Correlation,O
of,O
Chest,O
CT,STATE_OR_PROVINCE
and,O
RT,O
‐,O
PCR,O
Testing,O
in,O
Coronavirus,O
Disease,CAUSE_OF_DEATH
2019,DATE
(,O
COVID,O
‐,O
19,NUMBER
),O
in,O
China,COUNTRY
:,O
A,O
Report,O
of,O
1014,DATE
Cases,O
.,O
Radiology,O
2020,DATE
;,O
200642,NUMBER
.,O
[,O
Crossref,O
],O
Fang,O
Y,O
.,O
Zhang,PERSON
H,PERSON
.,O
Xie,PERSON
J,PERSON
.,O
et,O
al,O
.,O
Sensitivity,O
of,O
Chest,O
CT,STATE_OR_PROVINCE
for,O
COVID,O
‐,O
19,NUMBER
:,O
Comparison,O
to,O
RT,O
‐,O
PCR,O
.,O
Radiology,O
2020,DATE
;,O
200432,NUMBER
.,O
[,O
Crossref,O
],O
Luo,PERSON
L,PERSON
.,O
Liu,PERSON
D,O
.,O
Liao,PERSON
XL,O
.,O
et,O
al,O
.,O
Modes,O
of,O
contact,O
and,O
risk,O
of,O
transmission,O
in,O
COVID,O
‐,O
19,NUMBER
Yang,O
Y,O
.,O
Yang,O
M,O
.,O
Shen,O
C,O
.,O
et,O
al,O
.,O
Evaluating,O
the,O
accuracy,O
of,O
different,O
res,O
‐,O
piratory,O
specimens,O
in,O
the,O
laboratory,O
diagnosis,O
and,O
monitoring,O
the,O
viral,O
shedding,O
of,O
2019,DATE
‐,O
nCoV,O
infections,CAUSE_OF_DEATH
.,O
medRxiv,O
57,NUMBER
.,O
European,NATIONALITY
Cen,MISC
‐,O
tre,O
for,O
Disease,CAUSE_OF_DEATH
Prevention,O
and,O
pdf,O
on,O
4,DATE
April,DATE
2020,DATE
.,O
58,NUMBER
.,O
Centers,O
for,O
Disease,ORGANIZATION
Control,ORGANIZATION
and,ORGANIZATION
Prevention,ORGANIZATION
.,O
Discontinuation,O
of,O
Transmis,O
‐,O
sion,O
‐,O
Based,O
Precautions,O
and,O
Disposition,O
of,O
Patients,O
with,O
COVID,O
‐,O
19,NUMBER
in,O
Healthcare,O
Settings,O
(,O
Interim,O
Guidance,O
),O
.,O
Available,O
from,O
:,O
59,NUMBER
.,O
Wu,PERSON
X,O
.,O
Cai,O
Y,O
.,O
Huang,PERSON
X,PERSON
.,O
et,O
al,O
.,O
Co,O
‐,O
infection,CAUSE_OF_DEATH
with,O
SARS,O
‐,O
CoV,O
‐,O
2,NUMBER
and,O
in,O
‐,O
fluenza,O
A,O
virus,O
in,O
patient,O
with,O
pneumonia,CAUSE_OF_DEATH
.,O
China,COUNTRY
.,O
Emerg,O
Infect,O
Dis,O
2020,DATE
;,O
60,NUMBER
.,O
Wu,O
Z,O
.,O
McGoogan,PERSON
JM,PERSON
.,O
Characteristics,O
of,O
and,O
Important,O
Lessons,O
From,O
the,O
Coronavirus,O
Disease,CAUSE_OF_DEATH
2019,DATE
(,O
COVID,O
‐,O
19,NUMBER
),O
Outbreak,O
in,O
China,COUNTRY
:,O
Summary,O
of,O
a,O
Report,O
of,O
72314,NUMBER
Cases,O
From,O
the,O
Chinese,NATIONALITY
Center,O
for,O
Disease,ORGANIZATION
Control,ORGANIZATION
and,ORGANIZATION
Prevention,ORGANIZATION
.,O
JAMA,O
2020,DATE
;,O
61,NUMBER
.,O
Mao,PERSON
L,PERSON
.,O
Wang,PERSON
MD,STATE_OR_PROVINCE
.,O
Chen,PERSON
SH,PERSON
.,O
et,O
al,O
.,O
Neurological,O
manifestations,O
of,O
hospitalized,O
patients,O
with,O
62,NUMBER
.,O
Giacomelli,PERSON
A,O
.,O
Pezzati,PERSON
L,PERSON
.,O
Conti,PERSON
F,O
.,O
et,O
al,O
.,O
Self,O
‐,O
reported,O
Olfactory,O
and,O
Taste,O
Disorders,O
in,O
SARSCoV,O
‐,O
2,NUMBER
Patients,O
:,O
A,O
Cross,O
‐,O
Sectional,O
Study,O
.,O
Clin,O
Infect,O
Dis,O
2020,DATE
;,O
ciaa330,O
.,O
63,NUMBER
.,O
Xiang,PERSON
P,O
.,O
Xu,PERSON
XM,PERSON
.,O
Gao,PERSON
LL,PERSON
.,O
et,O
al,O
.,O
First,ORDINAL
case,O
of,O
2019,DATE
novel,O
coronavirus,O
disease,CAUSE_OF_DEATH
with,O
Encephalitis,MISC
.,O
ChinaXiv,O
T202003,TIME
.,O
00015,NUMBER
.,O
64,NUMBER
.,O
Xu,PERSON
Z,PERSON
.,O
Shi,O
L,O
.,O
Wang,O
Y,O
.,O
et,O
al,O
.,O
Pathological,O
findings,O
of,O
COVID,O
‐,O
19,NUMBER
associat,O
‐,O
ed,O
with,O
acute,O
respiratory,O
distress,O
syndrome,O
.,O
Lancet,O
Respir,O
Med,O
2020,DATE
;,O
8,NUMBER
:,O
65,NUMBER
.,O
Wu,O
Y,O
.,O
Xu,PERSON
X,PERSON
.,O
Chen,PERSON
Z,PERSON
.,O
et,O
al,O
.,O
Nervous,O
system,O
involve,O
‐,O
ment,O
after,O
infection,CAUSE_OF_DEATH
with,O
COVID,O
‐,O
19,NUMBER
and,O
other,O
coronaviruses,O
.,O
Brain,O
Behav,O
Immun,O
2020,DATE
;,O
S0889,O
‐,O
1591,DATE
(,O
20,NUMBER
),O
30357,NUMBER
‐,O
3,NUMBER
.,O
[,O
Crossref,O
],O
66,NUMBER
.,O
Guidance,O
for,O
the,O
role,O
and,O
use,O
of,O
non,O
‐,O
invasive,O
respiratory,O
support,O
in,O
adult,O
patients,O
with,O
COVID,O
‐,O
19,NUMBER
(,O
confirmed,O
or,O
suspected,O
),O
6,DATE
April,DATE
2020,DATE
.,O
67,NUMBER
.,O
Vitacca,PERSON
M,O
.,O
Nava,PERSON
S,O
.,O
Santus,O
P,O
.,O
et,O
al,O
.,O
Early,O
consensus,O
management,O
for,O
non,O
‐,O
ICU,O
ARF,O
SARS,O
‐,O
CoV,O
‐,O
2,NUMBER
emergency,O
in,O
Italy,COUNTRY
:,O
from,O
ward,O
to,O
trenches,O
.,O
Eur,O
Respir,O
J,O
2020,DATE
;,O
55,NUMBER
:,O
2000632,NUMBER
.,O
[,O
Crossref,O
],O
68,NUMBER
.,O
Cain,PERSON
DW,O
.,O
Cidlowski,O
JA,O
.,O
Immune,O
regulation,O
by,O
69,NUMBER
.,O
Wu,O
C,O
.,O
Chen,PERSON
X,PERSON
.,O
Cai,O
Y,O
.,O
et,O
al,O
.,O
Risk,O
Factors,O
Associated,O
With,O
Acute,O
Respiratory,O
Distress,O
Syn,O
‐,O
drome,O
and,O
Death,O
in,O
Patients,O
With,O
Coronavirus,O
Disease,CAUSE_OF_DEATH
2019,DATE
Pneumo,LOCATION
‐,O
nia,O
in,O
Wuhan,CITY
.,O
China,COUNTRY
.,O
JAMA,O
Intern,TITLE
Med,O
2020,DATE
;,O
e200994,O
.,O
[,O
Crossref,O
],O
70,NUMBER
.,O
Fowler,PERSON
AA,O
.,O
Truwit,PERSON
JD,PERSON
.,O
Hite,PERSON
RD,O
.,O
et,O
al,O
.,O
Effect,O
of,O
Vitamin,O
C,O
In,O
‐,O
fusion,O
on,O
Organ,O
Failure,O
and,O
Biomarkers,O
of,O
Inflammation,O
and,O
Vascu,O
‐,O
lar,O
Injury,O
in,O
Patients,O
With,O
Sepsis,CAUSE_OF_DEATH
and,O
Severe,O
Acute,O
Respiratory,O
Failure,O
.,O
The,O
CITRIS,O
‐,O
ALI,O
Randomized,O
Clinical,O
Trial,O
.,O
JAMA,O
2019,DATE
;,O
322,NUMBER
:,O
1261,DATE
‐,O
70,NUMBER
.,O
[,O
Crossref,O
],O
